DR. Tattoff 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 01, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'DR. TATTOFF, INC.	'	'
Entity Central Index Key	'0001294157	'	'
Trading Symbol	'tatt	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-Known Seasoned Issuer	'No	'	'
Entity Common Stock, Shares Outstanding	'	19,308,230	'
Entity Public Float	'	'	$0
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS	'	'
Cash and cash equivalents	$197,523	$318,394
Management fee due from related party	'	189,484
Prepaid expenses and other current assets	397,115	138,927
Total current assets	594,638	646,805
Property and Equipment, net	2,050,287	1,311,309
Other Assets	251,270	230,517
Total assets	2,896,195	2,188,631
CURRENT LIABILITIES	'	'
Accounts payable	869,313	504,074
Related party payables	23,622	'
Accrued expenses and other liabilities	587,598	502,052
Warrant liabilities	116,690	1,600
Deferred revenue	1,113,883	502,795
Accrued compensation	543,251	237,357
Proceeds of pending offering of convertible notes	'	200,000
Revolving line of credit	1,100,954	'
Notes payable, current portion (net of unamortized discount)	716,531	195,819
Convertible promissory notes, current portion (net of unamortized discount)	947,987	'
Capital lease obligations, current portion (related party)	10,286	50,574
Total current liabilities	6,030,115	2,194,271
LONG-TERM LIABILITIES	'	'
Notes payable, net of current portion	255,456	121,959
Convertible promissory notes, net of current portion and unamortized discount	328,388	452,779
Capital lease obligations, net of current portion (related party)	43,630	120,960
Deferred rent	251,597	104,740
Total liabilities	6,909,186	2,994,709
COMMITMENTS AND CONTINGENCIES (notes 8 and 10)	'	'
SHAREHOLDERS' DEFICIT	'	'
Preferred stock, 2,857,143 shares authorized, none issued or outstanding at December 31, 2013 and 2012	'	'
Common stock, $.0001 par value, 75,000,000 shares authorized, 19,308,230 and 18,332,803 shares issued and outstanding at December 31, 2013 and 2012, respectively	1,931	1,833
Additional paid-in capital	7,692,978	6,599,446
Accumulated deficit	-11,707,900	-7,407,357
Total shareholders' deficit	-4,012,991	-806,078
Total liabilities and shareholders' deficit	$2,896,195	$2,188,631

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]	'	'
Preferred stock, shares authorized	2,857,143	2,857,143
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	19,308,230	18,332,803
Common stock, shares outstanding	19,308,230	18,332,803

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues	'	'
Revenues from related party	$2,547,021	$2,722,528
Owned clinic revenues	1,107,579	477,614
Total revenues	3,654,600	3,200,142
Operating costs and expenses	'	'
Clinic operating expenses	3,353,765	2,472,117
General and administrative expenses	2,911,503	2,567,082
Marketing and advertising	776,064	622,037
Depreciation and amortization	397,413	282,068
Total operating costs and expenses	7,438,745	5,943,304
Loss from operations	-3,784,145	-2,743,162
Interest expense	-587,148	-115,881
Gain on sale of property and equipment	62,366	'
Other income	9,184	20,047
Loss before provision for income taxes	-4,299,743	-2,838,996
Provision for income taxes	800	800
Net loss	($4,300,543)	($2,839,796)
Basic and diluted net loss per share applicable to common shareholders (in dollars per share)	($0.23)	($0.18)
Weighted average shares outstanding - basic and diluted (in shares)	18,743,738	15,983,905

CONSOLIDATED_STATEMENTS_OF_SHA

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) (USD $)	Common Stock	Additional Paid-in Capital (Deficit)	Accumulated Deficit	Total
BALANCE at Dec. 31, 2011	$1,473	$4,465,307	($4,567,561)	($100,781)
BALANCE (in shares) at Dec. 31, 2011	14,727,344	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'
Services paid in stock	8	43,078	'	43,086
Services paid in stock (in shares)	87,930	'	'	'
Stock compensation expense	'	70,532	'	70,532
Warrants issued for consulting service	'	120,600	'	120,600
Stock options exercised	2	7,898	'	7,900
Stock options exercised (in shares)	21,428	'	'	'
Sale of common stock	350	1,712,740	'	1,713,090
Sale of common stock (in shares)	3,496,101	'	'	'
Beneficial conversion feature on convertible notes	'	31,066	'	31,066
Warrants issued with convertible notes	'	148,225	'	148,225
Net loss	'	'	-2,839,796	-2,839,796
BALANCE at Dec. 31, 2012	1,833	6,599,446	-7,407,357	-806,078
BALANCE (in shares) at Dec. 31, 2012	18,332,803	'	'	18,332,803
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'
Services paid in stock	71	349,848	'	349,919
Services paid in stock (in shares)	712,452	'	'	'
Stock compensation expense	'	136,151	'	136,151
Warrants issued for consulting service	'	116,824	'	116,824
Stock options exercised	4	17,489	'	17,493
Stock options exercised (in shares)	35,700	'	'	'
Sale of common stock	23	124,978	'	125,001
Sale of common stock (in shares)	227,275	'	'	'
Beneficial conversion feature on convertible notes	'	14,000	'	14,000
Warrants issued with convertible notes	'	334,242	'	334,242
Net loss	'	'	-4,300,543	-4,300,543
BALANCE at Dec. 31, 2013	$1,931	$7,692,978	($11,707,900)	($4,012,991)
BALANCE (in shares) at Dec. 31, 2013	19,308,230	'	'	19,308,230

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($4,300,543)	($2,839,796)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	397,413	282,068
Amortization of debt discount to interest	308,633	39,570
Stock compensation expense	136,151	70,532
Change in fair value of warrant liability	-7,415	-10,465
Services paid for in stock and warrants	466,744	163,686
Changes in operating assets and liabilities:	'	'
Management fee due from related party	189,484	94,439
Prepaid expenses and other current assets	-126,330	-33,482
Other assets	-28,863	-168,512
Accounts payable	365,239	64,776
Accrued expenses and other liabilities	83,769	277,816
Deferred revenue	611,088	317,828
Related party payable	23,622	-20,095
Accrued compensation	305,894	106,646
Deferred rent	-53,143	66,379
Net cash used in operating activities	-1,628,257	-1,588,610
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Purchases of property and equipment	-593,059	-490,842
Net cash used in investing activities	-593,059	-490,842
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Principal payments on capital lease obligations	-117,617	-64,604
Principal payments on notes payable	-430,386	-161,827
Proceeds from sale of common stock	125,001	1,713,090
Proceeds from issuance of convertible notes	885,000	592,500
Proceeds from issuance of short-term notes	520,000	'
Proceeds from pending offering of convertible notes	'	200,000
Proceeds from revolving line of credit	1,301,000	'
Repayments on revolving line of credit	-200,046	'
Proceeds from exercise of stock options	17,493	7,900
Net cash provided by financing activities	2,100,445	2,287,059
Net (decrease) increase in cash and cash equivalents	-120,871	207,607
Cash and cash equivalents - beginning of year	318,394	110,787
Cash and cash equivalents - end of year	197,523	318,394
Cash paid during the year for:	'	'
Interest	135,972	64,095
Taxes	800	800
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES	'	'
Acquisition of property and equipment through issuance of notes payable	535,222	165,786
Non-cash financing related to revolving line of credit	129,301	'
Financing of insurance premiums	$131,859	$59,765

ORGANIZATION_AND_NATURE_OF_OPE

ORGANIZATION AND NATURE OF OPERATIONS	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
ORGANIZATION AND NATURE OF OPERATIONS	'
	NOTE 1.	ORGANIZATION AND NATURE OF OPERATIONS
	Organization
	Dr. Tattoff, Inc., a Florida corporation formed in 2004, directly and through its wholly-owned subsidiaries, DRTHC I, LLC and DRTHC II, LLC, Delaware limited liability companies (collectively with Dr. Tattoff, Inc., the “Company”) operates clinics and provides marketing and practice management services to licensed physicians who primarily perform laser tattoo removal services.  The Company currently operates clinics in Dallas and Houston, Texas; Phoenix, Arizona; and Atlanta, Georgia, and provides services under a management services agreement with a contracting physician at four Southern California locations whereby the Company provides management, administrative, marketing and support services, insurance, and equipment at the clinical sites.  The contracting physician’s medical personnel provide laser tattoo and hair removal services.
	In February 2008, the Company completed a reverse merger with Lifesciences Opportunities Incorporated a “public shell” company, and became a Securities and Exchange Commission (“SEC”) registrant (the “Merger”).  The Company filed Form 10-Q for the quarters ended March 31, 2008 and June 30, 2008, but failed to file any Forms 10-Q or 10-K subsequently.  On March 16, 2010, the Company filed a Form 15 with the SEC to terminate its registration under Section 12(g) of the Securities Exchanges Act of 1934, as amended, (the “Exchange Act”). Upon the filing of the Form 15, the Company’s obligation to file periodic and other reports with the SEC was immediately suspended.  On December 7, 2011 the Company filed a registration statement on Form 10 with the SEC to register its common stock pursuant to Section 12(g) of the Exchange Act, which was subsequently amended on December 23, 2011 and January 20, 2012.  The amended registration statement became effective on February 6, 2012.
	Increase in Authorized Shares and Reverse Stock Split
	In February 2011, the Company amended its Articles of Incorporation to increase the number of authorized shares to 28,571,429, consisting of 25,714,286 shares of common stock, par value $.0001 per share and 2,857,143 shares of preferred stock.  Series of preferred stock may be created and issued from time to time, with such designations, preferences, rights and restrictions as shall be stated in resolutions adopted by the Board of Directors.
	In February 2012, the Company amended its Articles of Incorporation to effect a 7-for-1 reverse stock split. Earnings per share amounts, weighted average common shares outstanding, shares issued and outstanding, exercise prices, and fair value per share amounts for all periods have been adjusted to reflect the Company’s 7-for-1 reverse stock split.  Par value per share was unchanged with the difference between the originally calculated par value of issued and outstanding shares and the adjusted amounts reclassified to additional paid-in capital for all periods.
	In June 2012, the Company amended its Articles of Incorporation to increase the number of shares of the Company’s common stock authorized for issuance from 25,714,286 shares to 75,000,000 shares.
	Going Concern
	The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the ordinary course of business.  At December 31, 2013, the Company has accumulated losses approximating $11,708,000, current liabilities that exceeded its current assets by approximately $5,435,000, shareholders’ deficit of approximately $4,013,000, and has not yet produced operating income or positive cash flows from operations.  The Company’s ability to continue as a going concern is predicated on its ability to raise additional capital, increase sales and margins, and ultimately achieve sustained profitable operations.  The uncertainty related to these conditions raises substantial doubt about the Company’s ability to continue as a going concern.  The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Management believes that the Company will need to continue to raise additional outside capital to expand the number of clinics in operation and to address its losses and ability to continue to operate.  The Company intends to raise additional capital and continue opening additional clinics to achieve this goal.
	In addition, the Company expanded its Board of Directors in 2010 to include individuals with substantial experience in raising capital and numerous relationships that may assist the Company in achieving its goals.  In the event that the Company is unsuccessful in raising adequate equity capital, management will attempt to reduce losses and preserve as much liquidity as possible. Steps management would likely take would include limiting capital expenditures, reducing expenses and leveraging the relatively few assets that it owns without encumbrance.  A reduction in expenses would likely include personnel costs, professional fees, and marketing expenses.  While management would attempt to achieve break-even or profitable operations through these steps, there can be no assurance that it will be successful.
	Consolidation Policy
	The Company has various contractual relationships with William Kirby, D.O., Inc. including a management services agreement, medical director’s agreement, equipment subleases, and guarantees.  The Company evaluated the various relationships between the parties to determine if it should consolidate William Kirby, D.O., Inc. as a variable interest entity pursuant to ASC 810, Consolidation.  The Company determined that it was not the primary beneficiary of the interest due to the following: William Kirby, D.O., Inc. has the ability to control the activities that have the most significant impact on its economic performance; the Company does not have an obligation to absorb losses of William Kirby, D.O., Inc.; the Company is not guaranteed a return; and there are no interests that are subordinate to the equity interest at risk.  The Company conclusion followed an analysis of both the contractual arrangements and California state law restrictions on relationships between licensed professionals and businesses.  Among the restrictions of California law the Company considered most relevant in its analysis were those that prohibit a lay corporation from providing medical services, including laser tattoo and laser hair removal, employing medical personnel, and making key decisions about equipment and marketing initiatives. Therefore, the results of William Kirby, D.O., Inc. are not consolidated into the results of the Company.
	The carrying amount and classification of assets and liabilities in the accompanying consolidated balance sheets relating to the Company’s relationship with William Kirby, D.O., Inc. are summarized as follows:
			December 31,
			2013		2012
	Current Assets
	Management fee due from related party		$	-	$	189,484
	Non-Current Assets
	Assets under capital lease, net			-		39,064
	Current Liabilities
	Related party payables			23,622		-
	Capital lease obligations, current portion			10,286		50,574
	Long-Term Liabilities
	Capital lease obligations, net of current portion			43,630		120,960
	The Company may be exposed to losses under its relationship with William Kirby, D.O., Inc.  The Company’s most significant exposure to loss in the relationship is under the management services agreement.  Losses could occur if the management fees are inadequate to cover the Company’s costs of providing the management services.  The Company is unable to estimate its maximum exposure to such losses.
	The Company’s relationship and agreements with William Kirby, D.O., Inc. and Dr. Kirby are further described in Note 7, “Capital Lease Obligations (Related Party)”; Note 8, “Related Party Transactions” and Note 10, “Commitments and Contingencies.”
	Dr. Tattoff, Inc. formed two wholly owned subsidiaries, DRTHC I, LLC and DRTHC II, LLC that are responsible for the operations of some of the new clinics that the Company has established.  The consolidated financial statements include the accounts of DRTHC I, LLC and DRTHC II, LLC.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The accompanying consolidated financial statements of Dr. Tattoff, Inc. and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
	Cash and Cash Equivalents
	The Company considers all highly liquid short-term investments with original maturity of three months or less to be cash equivalents.
	Fair Value of Financial Instruments
	The Company adopted the fair value measurement and disclosure requirements of ASC 820, Fair Value Measurements and Disclosure for financial assets and liabilities measured on a recurring basis.  ASC 820 defines fair value, establishes a framework for measuring fair value under GAAP and expands disclosures about fair value measurements.  This standard applies in situations where other accounting pronouncements either permit or require fair value measurements. ASC 820 does not require any new fair value measurements.
	Fair value is defined in ASC 820 as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The standard describes three levels of inputs that may be used to measure fair value:
	Level 1:	Quoted prices in active markets for identical or similar assets and liabilities.
	Level 2:	Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
	Level 3:	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s financial instruments include cash and cash equivalents, management fee due from related party, prepaid expenses and other current assets, other assets, accounts payable, related party payable, accrued expenses and other liabilities, deferred revenue, accrued compensation, capital lease obligations, convertible promissory notes, notes payable, and warrant liabilities.  The carrying amounts of management fee due from related party, prepaid expenses and other current assets, other assets, accounts payable, related party payable, accrued expenses and other liabilities, deferred revenue and accrued compensation approximate their fair values due to the short maturity of these instruments.  The carrying amounts of capital leases, convertible promissory notes, and notes payable approximates their fair value as these instruments earn or are charged interest based on prevailing rates. The fair value of warrants is measured using level 3 inputs.
	Long-lived Assets
	Long-lived assets are reviewed for impairment in accordance with ASC No. 360 “Accounting for the Impairment or Disposal of Long-Lived Assets,” which requires impairment losses to be recorded on long-lived assets when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  For purposes of the impairment review, assets are reviewed on an asset-by-asset basis. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of each asset to future net cash flows on an undiscounted basis expected to be generated by such asset.  If such assets are considered to be impaired, the impairment to be recognized is measured by the amount which the carrying amount of the assets on an undiscounted basis exceeds the fair value of the assets.
	The major long-lived assets of the Company are the lasers and Intense Pulse Light, or IPL devices.  While the Company has sustained losses, the clinics where the lasers and IPL devices are located are either profitable or new and expected to be profitable.  As a result, recoverability of assets to be held and used is measured by a comparison of the carrying amount of each asset to future net cash flows on an undiscounted basis expected to be generated by such asset in each clinic.  There were no impairments of long-lived assets at December 31, 2013 and 2012.
	Property and Equipment
	Property and equipment is recorded at cost, less accumulated depreciation.  Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets.  The Company uses the following estimated useful lives for computing depreciation expense: furniture and fixtures, 7 years; medical equipment, 7 years; other equipment, 3 to 5 years.  Amortization of leasehold improvements is recorded using the straight-line method based on the lesser of the useful life of the improvement or the lease term, which is typically five years or less.
	Debt and Other Financial Instruments
	Debt/Equity Instruments Issued with Warrants
	The Company estimates the relative fair values of the debt and warrants, and allocates the proceeds pro-rata based on these values. The allocation of proceeds to the warrants results in the debt instrument being recorded at a discount from the face amount of the debt and the value allocated to the warrant is recorded to additional paid-in capital.
	The Company reviews the terms of convertible financial instruments it issues to determine whether there are embedded derivative instruments, including the conversion option that may be required to be bifurcated and accounted for separately as a derivative financial instrument.  In circumstances where the convertible instrument contains more than one embedded derivative, including the conversion option that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	When the convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds from the convertible host instruments are first allocated to the bifurcated derivative instruments.  The remaining proceeds, if any, are then allocated to the convertible instruments themselves, resulting in those instruments being recorded at a discount from their face value.
	Derivative Financial Instruments
	Derivative instruments are initially recorded at estimated fair value and are then revalued at each reporting date with changes in the estimated fair value reported as charges or credits to income.
	Revenue Recognition
	Currently, the majority of the Company’s revenues are derived from management services provided to William Kirby D.O., Inc., a related party, for our non-owned clinics.  The Company provides nonmedical services and facilities based on contractual prices established in advance that extend continuously over a set time for a fixed percentage of the contracting physician’s gross revenues (as defined in the Management Services Agreement - See Note 8, “Related Party Transactions”) with no upfront fees paid by William Kirby D.O., Inc.  The management services agreement with William Kirby D.O., Inc. covers all of the Company’s California locations.
	Under the management service agreement with William Kirby D.O., Inc., there is no right to refund or rejection of services.  The Company recognizes revenue when the following criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  Management services fees are paid by the contracting physician to the Company on a bi-weekly basis as earned, which is when the Company has substantially performed management services pursuant to the terms of the management services agreement with William Kirby D.O., Inc.
	The Company operates the Dallas, Houston, Atlanta and Phoenix locations directly, not pursuant to a management services agreement with a physician. Accordingly, patients contract with the Company and pay for the services they receive directly to the Company.  The Company recognizes revenue when the following criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  The Company requires payment at the time of the patient visit or in advance of the visit by those patients purchasing packages of treatments. Payments by patients made in advance of service delivery are recorded as “deferred revenue” on the accompanying consolidated balance sheets and amounted to approximately $1,114,000 at December 31, 2013 and $503,000 at December 31, 2012.
	Patients who purchase a package of tattoo removal services at clinics the Company operates directly are eligible to participate in the Company’s tattoo removal guarantee program.  Pursuant to the guarantee program, if the tattoo is not fully removed within the recommended number of treatments, the Company will continue to provide additional treatments, consistent with the Company’s medical protocols, for a period of up to one year following the date of the last paid treatment.  The Company estimates the cost of the guarantee program based on historical usage and the average cost of treatments.  The cost of the program is accrued on a per visit basis as visits occur and is included in clinic operating expense on the accompanying consolidated statements of operations.  The Company recognized accrued expense of approximately $77,000 and $37,000 as of December 31, 2013 and December 31, 2012, respectively, related to the guarantee program, and this is included in the accrued expenses and other liabilities in the accompanying consolidated balance sheets.  Patients who purchase a package of services and experience complete removal prior to completion of the package are eligible for a refund for the unused portion of the package.  The Company recognizes refunds, which have been immaterial in amount, as a reduction in revenue as incurred.  Patients who receive services in clinics operated under the management services agreement with William Kirby, D.O., Inc. are eligible for similar programs, which may reduce the management fee that the Company receives.
	Advertising Costs
	Advertising costs are expensed as incurred.  For the years ended December 31, 2013 and 2012, advertising expense was approximately $570,000 and $359,000, respectively, and is included in marketing and advertising in the accompanying consolidated statement of operations.
	Income Taxes
	The Company accounts for income taxes in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740 “Income taxes.”  Under ASC 740, deferred income taxes are recognized to reflect the tax consequences in future years for the differences between the amounts of assets and liabilities recognized for financial reporting purposes and such amounts recognized for income tax reporting purposes using enacted tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided to reduce net deferred tax assets to amounts that are more likely than not to be realized.
	The Company has incurred tax net operating losses since inception and, accordingly, has a deferred tax asset related to such tax net operating loss carryforwards.  The Company has provided a 100% valuation allowance on such deferred tax asset at December 31, 2013 and 2012 (See Note 11, “Income Taxes”).
	The Company accounts for uncertainty in income taxes in accordance with ASC 740-10, which prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  ASC 740-10 also provides guidance on the measurement, derecognition, classification and disclosure of tax positions, as well as the accounting for related interest and penalties.  The Company’s policy is to recognize interest and penalties that would be assessed in relation to the settlement value of unrecognized tax benefits as a component of income tax expense.  The Company has recognized no tax related interest or penalties since the adoption of ASC 740-10.  As of December 31, 2013, the open tax years of the Company were 2009 to 2013.
	Earnings Per Share
	Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period.  Diluted earnings per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company.  In computing diluted earnings per share, the treasury stock method assumes that outstanding options are exercised and the proceeds are used to purchase common stock at the average market price during the period.  Options will have a dilutive effect under the treasury stock method only when the Company reports net income and the average market price of the common stock during the period exceeds the exercise price of the options.  Options, warrants and conversions of convertible debt instruments were not included in computing diluted earnings per share for the years ended December 31, 2013 and 2012, respectively because their effects were antidilutive.
	The following table illustrates the computation of basic and diluted earnings per share:
			2013			2012
	Net loss available to common stockholders (numerator)		$	(4,300,543	)	$	(2,839,796	)
	Weighted average shares outstanding (denominator)			18,743,738			15,983,905
	Basic and diluted EPS		$	(.23	)	$	(.18	)
	Basic and diluted EPS are the same for all periods presented as the impact of all potentially dilutive securities were anti-dilutive. The following potentially dilutive securities were not included in the computation of diluted EPS because to do so would have been anti-dilutive for the periods presented.
			2013			2012
	Warrants			6,508,415			3,150,434
	Common stock options			1,540,402			1,048,351
	Convertible promissory notes			2,387,510			987,500
				10,436,327			5,186,285
	Accounting for Common Stock Options
	The Company measures stock-based compensation expense at the grant date, based on the fair value of the award, and recognizes the expense over the employee’s requisite service (vesting) period using the straight-line method.  The measurement of stock-based compensation expense is based on several criteria including, but not limited to, the valuation model used and associated input factors, such as expected term of the award, stock price volatility, risk free interest rate and forfeiture rate.  Certain of these inputs are subjective to some degree and are determined based in part on management’s judgment.  The Company recognizes the compensation expense on a straight-line basis for its graded vesting awards.  Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.  However, the cumulative compensation expense recognized at any point in time must at least equal the portion of the grant-date fair value of the award that is vested at that date. As used in this context, the term “forfeitures” is distinct from “cancellations” or “expirations”, and refers only to the unvested portion of the surrendered equity awards.
	Deferred Rent
	The Company currently leases all of its locations under leases classified as operating leases.  Minimum base rent for these operating leases, which generally have escalating rentals over the term of the lease is recorded on a straight-line basis over the lease term.  As such, an equal amount of rent expense is attributed to each period during the term of the lease regardless of when actual payments occur.  Lease terms begin on the inception date and include option periods only where such renewals are imminent and assured.  The difference between rent expense and actual cash payments is classified as “deferred rent” in the accompanying consolidated balance sheets and approximated $252,000 and $105,000 at December 31, 2013 and 2012, respectively.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.  Actual results could differ from those estimates.  Significant estimates include those related to the realization of long-lived assets, deferred income tax asset valuation allowances, and the valuation of equity instruments issued.
	Concentrations
	Financial instruments that subject the Company to credit risk consist primarily of cash and revenues.  The Company’s cash and cash equivalents are maintained at financial institutions in the United States.  These accounts are insured by the Federal Deposit Insurance Corporation (“FDIC”).  At times, such balances may be in excess of the amounts insured by the FDIC.  The Company has not experienced any losses on such accounts and believes it is not exposed to any significant credit risks on its cash and cash equivalents.
	A significant portion of the Company’s revenues in 2013 and 2012 were derived from a management services agreement relating to the Company’s California clinics pursuant to a management services agreement with William Kirby D.O., Inc.  If the Company’s management services agreement is terminated for any reason or William Kirby, D.O., Inc. defaults on its obligations thereunder, the Company’s operating results, cash flows and financial performance may be adversely affected and the Company may need to negotiate and enter into a new agreement with a qualified physician.  Although the Company’s management services agreement provides the Company with the right to approve a replacement contracting physician upon termination or default, the Company can give no assurance that it will be able to expeditiously identify and contract with a qualified replacement physician on commercially reasonable terms or at all.  The termination of the Company’s management services arrangement could have a material adverse effect on the Company’s consolidated financial condition, cash flows and results of operations.
	Significant Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board issued Accounting Standards Update No. 2013-11, Income Taxes (Topic 740) (“ASU 2013-11”), which requires the financial statement presentation of an unrecognized tax benefit in a particular jurisdiction, or a portion thereof, as a reduction to a deferred tax asset for a net operating loss (“NOL”) carryforward, a similar tax loss, or a tax credit carryforward, unless the uncertain tax position is not available to reduce, or would not be used to reduce, the NOL or carryforward under the tax law in the same jurisdiction; otherwise, the unrecognized tax benefit should be presented as a gross liability and should not be combined with a deferred tax asset. ASU 2013-11 is effective for interim and annual periods beginning after December 15, 2013. The Company does not expect that this new guidance will have a significant impact on the Company’s consolidated financial position, results of operations or cash flows.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants (“AICPA”), and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
PROPERTY AND EQUIPMENT	'
	NOTE 3.	PROPERTY AND EQUIPMENT
	Property and equipment, consists of the following at December 31:
			2013			2012
	Equipment		$	1,824,871		$	1,382,005
	Furniture and fixtures			136,426			93,129
	Leasehold improvements			1,217,223			803,335
				3,178,520			2,278,469
	Less accumulated depreciation and amortization			(1,128,233	)		(967,160	)
			$	2,050,287		$	1,311,309
	Depreciation and amortization expense was approximately $397,000 and $282,000 for the years ended December 31, 2013 and 2012, respectively.
	Assets under capital leases (gross) were approximately $159,000 and $511,000 at December 31, 2013 and 2012, respectively.  Amortization expense recorded for the assets under capital leases amounted to approximately $12,000 and $35,000 for the years ended December 31, 2013 and 2012, respectively and is included in the depreciation and amortization amounts noted above.  Accumulated amortization of assets under capital leases was approximately $159,000 and $471,000 at December 31, 2013 and December 31, 2012, respectively.
	In October 2013, the Company purchased three lasers it had previously held under capital lease obligations from the related party lessor for aggregate consideration of $75,000. In December 2013, the Company sold these assets to an unrelated third party in connection with the Company’s acquisition of three new lasers. These assets were  previously held on the books of the Company at a gross amount of $228,000 and were fully amortized. The Company recorded a gain of $62,000 related to this sale as noted on the consolidated statements of operations.

REVOLVING_LINE_OF_CREDIT

REVOLVING LINE OF CREDIT	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
REVOLVING LINE OF CREDIT	'
	NOTE 4.	REVOLVING LINE OF CREDIT
	In December 2013, the Company entered into a revolving line of credit with a lender with an initial commitment of $1,300,000 and a maximum revolving commitment of $7,000,000. Increase in the commitment above $1,300,000 is at the sole and absolute discretion of the lender. The term of the revolving loan is for six months subject to two automatic six month extensions as long as the Company is not in default on the credit agreement. The line of credit is secured by a second lien on all encumbered equipment of the Company and a first lien on all other assets of the Company.
	The credit agreement requires that all receipts of the Company, except receipts received from investors and receipts from landlords for tenant improvement allowances, be deposited in a lockbox account controlled by the lender. Provided the Company is not in default, it can draw from the lockbox an amount equal to all of the funds deposited in the lockbox less fees and expenses due the lender and a mandatory principal repayment equal to 2% of the funds deposited in the lockbox. The Company deposited $130,000 in the lockbox account as a mandatory principal payment at the time that the loan closed. At December 31, 2013, these funds remain in the lockbox and are unavailable to the Company to draw upon. As a result, the Company recorded a $130,000 reduction in the loan balance. At December 31, 2013, the Company had deposits in the lockbox account of approximately $65,000 available for draw under the revolving line of credit. Cash deposited in the lockbox by the Company in excess of fees and expenses due the lender and the mandatory 2% principal payment are recorded as a further reduction in the loan balance.
	The outstanding principal balance of the loan, which is reduced by funds in the lockbox account, bears interest at 10% per annum and requires a surcharge in the form of a receipts collection fee such that the aggregate interest and receipts collection fee do not exceed 1.5% of the outstanding principal per month. In addition, the Company is obligated to pay an asset monitoring fee of $1,500 per quarter and certain other expenses of the lender. In connection with the initial closing of the revolving line of credit, the Company paid the lender fees for transaction advisory services, due diligence, legal review and related expenses and finder’s fees totaling $136,850 in cash. Additionally, the Company paid a financial advisory firm $26,000 in cash for services in connection with the loan.
	In addition to the cash consideration, the Company issued 125,000 shares of its common stock to the lender. The common stock is subject to a make whole provision such that the value of the common stock issued to the lender is not less than nor can ever be more than $125,000. The Company also issued fully vested three-year, callable warrants to three organizations affiliated to the financial advisory firm to purchase up to an aggregate of 39,000 shares of its common stock at an exercise price of $.78 per share in connection with the loan.  Loan costs are included in prepaid expenses and are being amortized to interest expense over the initial six month term of the loan.
	So long as the revolving note is outstanding, but only upon the occurrence and during the continuance of an event of default, and subject to certain limitations, the lender may convert all or any portion of the amounts due it into common stock of the Company. Beginning with the first quarter of 2014 the Company is subject to a financial covenant which requires that its sales revenue be not less than 75% of its sales revenue for the corresponding quarter of the prior year.

NOTES_PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2013
Notes Payable [Abstract]	'
NOTES PAYABLE	'
	NOTE 5.	NOTES PAYABLE
	Notes payable consist of the following at December 31:
			2013			2012
	Financed insurance premiums		$	-		$	4,510
	Equipment promissory notes			674,474			313,268
	Tenant improvement secured loans			100,000			-
	Unsecured promissory notes			300,000			-
				1,074,474			317,778
	Less unamortized discount			(102,487	)		-
	Less current portion (net of unamortized discounts)			(716,531	)		(195,819	)
			$	255,456		$	121,959
	Financed Insurance Premiums
	In March 2012, the Company entered into a financing agreement with an unrelated third party to finance the Company’s directors and officer liability insurance for a period of 12 months.  The note, in the principal amount of $44,200, bears interest at approximately 4.87% per annum, and is repayable in 10 monthly installments of $4,519.  The note matured in January 2013 and was paid in full at that time.  The balance outstanding on the note was $0 and $4,510 at December 31, 2013 and December 31, 2012, respectively.
	Equipment Promissory Notes
	In November 2010, the Company entered into a financing agreement with an unrelated third party to finance computer and telephone equipment to upgrade existing systems and equip its clinic location in Montclair, California.  The note, in the principal amount of $64,157, bears interest at approximately 6% per annum, and is repayable in 60 monthly payments of $1,241.  The note matures in October 2015 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon.  The balance outstanding on the note was $27,994 and $40,779 at December 31, 2013 and December 31, 2012, respectively.
	In February 2011, the Company entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a laser for the location in Montclair, California.  The note, in the principal amount of $118,495, bears interest at approximately 7% per annum, and is repayable in 36 monthly installments of $3,700.  The note matures in January 2014 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon.  The balance outstanding on the note was $43,020 and $54,030 at December 31, 2013 and December 31, 2012, respectively.
	In May 2011, the Company entered into a financing agreement with an unrelated third party to finance computer and telephone equipment for its Dallas, Texas clinic and its call center in Irvine, California.  The note, in the principal amount of $17,515, bears interest at approximately 7% per annum, and is repayable in 36 monthly payments of $539.  The note matures in June 2014 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon.  The balance outstanding on the note was $3,171 and $9,201 at December 31, 2013 and December 31, 2012, respectively.
	In June 2011, the Company entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a laser for the location in Dallas, Texas.  The note, in the principal amount of $118,495, bears interest at approximately 7% per annum, and is repayable in 36 monthly installments of $3,700.  The note matures in June 2014 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon.  The balance outstanding on the note was $49,390 and $67,186 at December 31, 2013 and December 31, 2012, respectively.
	In June 2012, the Company entered into a financing agreement with an unrelated third party to finance computer and telephone equipment for its Houston, Texas clinic and its clinic planned for Phoenix, Arizona.  The note, in the principal amount of $37,870, bears interest at approximately 6% per annum, and is repayable in 36 monthly payments of $1,148.  The note matures in May 2015 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon.  The balance outstanding on the note was $18,697 and $31,008 at December 31, 2013 and December 31, 2012, respectively.
	In June 2012, DRTHC I, LLC, a wholly-owned subsidiary of the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a laser for the location in Houston, Texas.  The note, in the principal amount of $59,920, bears interest at approximately 7% per annum, and is repayable in 24 monthly installments of $2,683. The note matures in June 2014 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon.  The balance outstanding on the note was $15,773 and $45,715 at December 31, 2013 and December 31, 2012, respectively.
	In November 2012, DRTHC I, LLC, a wholly-owned subsidiary of the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a laser for the location in Phoenix, Arizona.  The note, in the principal amount of $67,996, bears interest at approximately 7% per annum, and is repayable in 24 monthly installments of $3,044. The note matures in November 2014 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon.  The balance outstanding on the note was $32,345 and $65,349 at December 31, 2013 and December 31, 2012, respectively.
	In March 2013, the Company entered into a financing agreement with an unrelated third party to finance telephone equipment for its Sugar Land, Texas clinic and clinics planned for Fort Worth, Texas and Atlanta, Georgia.  The note, in the principal amount of $29,347, bears interest at approximately 9% per annum, and is repayable in 36 monthly payments of $1,037.  The note matures in February 2016 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon.  The balance outstanding on the note was $22,538 and $0 at December 31, 2013 and December 31, 2012, respectively.
	In March 2013, the Company entered into a financing agreement with an unrelated third party to finance computer equipment for its Sugar Land, Texas clinic and clinics planned for Fort Worth, Texas and Atlanta, Georgia.  The note, in the principal amount of $37,524, bears interest at approximately 11% per annum, and is repayable in 36 monthly payments of $1,199.  The note matures in February 2016 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon.  The balance outstanding on the note was $28,590 and $0 at December 31, 2013 and December 31, 2012, respectively.
	In March 2013, DRTHC I, LLC, a wholly-owned subsidiary of the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a laser for the Sugar Land, Texas clinic.  The note, in the principal amount of $75,920, bears interest at approximately 7% per annum, and is repayable in 24 monthly installments of $3,399.  The note matures in March 2015 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon. The balance outstanding on the note was $48,485 and $0 at December 31, 2013 and December 31, 2012, respectively. The Company relocated the laser to its Frisco, Texas clinic in March 2014.
	In October 2013, DRTHC II, LLC, a wholly-owned subsidiary of the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of lasers for the Atlanta, Georgia clinic.  The note, in the principal amount of $114,000, bears interest at approximately 7% per annum, and is repayable in 24 monthly installments of $5,104.  The note matures in November 2015 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon. The balance outstanding on the note was $109,561 and $0 at December 31, 2013 and December 31, 2012, respectively.
	In October 2013, DRTHC I, LLC, a wholly-owned subsidiary of the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of a hair removal device for the Houston, Texas clinic.  The note, in the principal amount of $28,000, bears interest at approximately 7% per annum, and is repayable in 24 monthly installments of $1,254.  The note matures in November 2015 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon. The balance outstanding on the note was $26,910 and $0 at December 31, 2013 and December 31, 2012, respectively.
	In December 2013, the Company, entered into a financing agreement with an unrelated third party manufacturer to finance the purchase of three laser devices for its clinics in Southern California.  The note, in the principal amount of $248,000, bears interest at approximately 7% per annum, and is repayable in 24 monthly installments of $11,104.  The note matures in December 2015 and is secured by a first priority purchase money security interest in the equipment.  The Company is required to maintain and insure the equipment secured by the note and pay personal property taxes thereon. The balance outstanding on the note was $248,000 and $0 at December 31, 2013 and December 31, 2012, respectively.
	Tenant Improvement Secured Loans
	In February 2013, the Company issued $200,000 in notes, secured by the reimbursements due from landlords with respect to tenant improvements made or to be made by the Company in connection with the development of clinics.  The notes bear interest at 15% and are were initially due on August 15, 2013.  As additional consideration for the investors purchasing the notes, the Company issued the note holders fully vested five-year warrants to purchase an aggregate of 218,750 shares of the Company’s common stock at an exercise price of $.60 per share.  The relative fair values of the warrants at the time of issuance, determined by management to be $49,454 in the aggregate, were recorded as a debt discount and will be amortized to interest expense over the term of the notes.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.60, expected life of five years; risk free interest rate of .08%; volatility of 72% and expected dividend yield of zero.
	In July 2013, the Company issued five-year fully vested warrants to purchase 220,000 shares of Company common stock at an exercise price of $.60 per share to the note holders in exchange for their agreement to extend the original due date from August 15, 2013 to December 31, 2013. The relative fair values of the warrants at the time of issuance, determined by management to be $52,500 in the aggregate, were recorded as a debt discount and will be amortized to interest expense over the remaining term of the notes. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.60, expected life of five years; risk free interest rate of 1.42%; volatility of 63% and expected dividend yield of zero.
	In December 2013, the Company repaid $100,000 principal amount of its tenant improvement secured loans together with interest due thereon of approximately $15,238 to three note holders, one of whom is an officer of the Company, and entered into extension agreements with respect to the remaining outstanding balance of $100,000. In exchange for an extension of the due date of the notes through March 31, 2014, the Company issued the note holders fully vested five-year warrants to purchase an aggregate of 115,240 shares of the Company’s common stock at an exercise price of $.60 per share.  The fair value of the warrants at the time of issuance, determined by management to be $27,700 in the aggregate, was recorded as additional debt discount and will be amortized to interest expense over the term of the extension.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.60, expected life of five years; risk free interest rate of 1.73%; volatility of 63% and expected dividend yield of zero.
	Amortization of the debt discount was $101,954 for the year ended December 31, 2013 and $0 for the year ended December 31, 2012.
	Unsecured Promissory Notes
	In August 2013, the Company issued $120,000 in unsecured promissory notes to three members of its Board of Directors, their families, associates or associated entities.  The notes bear interest at 15% and were due on December 31, 2013.  As additional consideration for the investors purchasing the notes, the Company issued the note holders fully vested five-year warrants to purchase an aggregate of 120,000 shares of the Company’s common stock at an exercise price of $.60 per share.  The relative fair values of the warrants at the time of issuance, determined by management to be $22,800 in the aggregate, were recorded as a debt discount and were amortized to interest expense over the term of the notes.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.60, expected life of five years; risk free interest rate of 1.48%; volatility of 63% and expected dividend yield of zero.  Amortization of the debt discount was $22,800 for the year ended December 31, 2013 and $0 for the year ended December 31, 2012.
	In October 2013, the Company issued $200,000 in unsecured promissory notes to a 5% shareholder.  The notes bear interest at 15% and were initially due on December 31, 2013.  As additional consideration for the investors purchasing the notes, the Company issued the note holders fully vested five-year warrants to purchase an aggregate of 200,000 shares of the Company’s common stock at an exercise price of $.60 per share.  The relative fair values of the warrants at the time of issuance, determined by management to be $38,000 in the aggregate, were recorded as a debt discount and were amortized to interest expense over the term of the notes.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.60, expected life of five years; risk free interest rate of 1.48%; volatility of 63% and expected dividend yield of zero.  Amortization of the debt discount was $38,000 for the year ended December 31, 2013 and $0 for the year ended December 31, 2012.
	In December 2013, the Company repaid $20,000 principal amount of its unsecured promissory notes together with interest due thereon of approximately $1,159 to one note holder, an officer of the Company, and entered into extension agreements with respect to the remaining outstanding balance of unsecured promissory notes of $300,000. In exchange for an extension of the due date of the notes through March 31, 2014, the Company issued the note holders fully vested five-year warrants to purchase an aggregate of 310,893 shares of the Company’s common stock at an exercise price of $.60 per share.  The fair value of the warrants at the time of issuance, determined by management to be $74,771 in the aggregate, was recorded as additional debt discount and will be amortized to interest expense over the term of the extension.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.60, expected life of five years; risk free interest rate of 1.73%; volatility of 63% and expected dividend yield of zero.  Amortization of the debt discount related to the extension was $0 for the year ended December 31, 2013.
	The following table sets forth the future maturities of the Company’s outstanding notes payable, net of unamortized discount:
		Year ended
		December 31,
		2014		$	716,531
		2015			250,016
		2016			5,440
		Total		$	971,987

CONVERTIBLE_PROMISSORY_NOTES

CONVERTIBLE PROMISSORY NOTES	12 Months Ended
	Dec. 31, 2013
Convertible Promissory Notes [Abstract]	'
CONVERTIBLE PROMISSORY NOTES	'
	NOTE 6.                 CONVERTIBLE PROMISSORY NOTES
	Convertible promissory notes payable consist of the following at December 31:
			2013			2012
	Secured senior subordinated convertible promissory notes		$	892,500		$	592,500
	Senior subordinated convertible promissory notes			585,000			-
				1,477,500			592,500
	Less unamortized discount			(201,125	)		(139,721	)
	Less current portion (net of unamortized discounts)			(947,987	)		-
			$	328,388		$	452,779
	Secured Senior Subordinated Convertible Promissory Notes
	In May 2012, August 2012, September 2012, October 2012 and January 2013, the Company issued $200,000, $255,000, $50,000, $87,500 and $300,000 of secured senior subordinated convertible promissory notes, respectively to two members of the Company’s Board of Directors, their associates or associated entities, and others.  The notes are convertible at the option of the holder at any time during the term of the note into common stock of the Company at an initial conversion price of $.60 per share, subject to adjustment for stock splits or subdivisions.  The notes bear interest at 12% per annum, are payable quarterly, and are due at maturity.  The notes mature in May 2014 or December 2015 (with respect to the notes issued in January 2013) and are secured by a first priority lien on the ownership interest of the Company in its wholly-owned subsidiary DRTHC I, LLC or DRTHC II, LLC (with respect to the notes issued in January 2013).  The balance outstanding on the notes was $892,500 and $592,500 at December 31, 2013 and December 31, 2012 respectively.  As additional consideration for the investors purchasing the notes, the Company issued the note holders five-year warrants to purchase an aggregate of 1,115,625 shares of the Company’s common stock at an exercise price of $.75 per share.
	The relative fair values of the warrants at the time of issuance, determined by management to be $217,225 in the aggregate, were recorded as a debt discount and will be amortized to interest expense over the term of the notes.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.75, expected life of five years; risk free interest rate of .52-.72%; volatility of 72% and expected dividend yield of zero.  The notes also contained a beneficial conversion feature determined by management to be $45,066 in the aggregate which was recorded as a debt discount and will be amortized to interest expense over the term of the notes.  Amortization of the debt discount was $129,282 for the year ended December 31, 2013 and $39,570 for the year ended December 31, 2012.
	Senior Subordinated Convertible Promissory Notes
	In May 2013, June 2013 and July 2013, the Company issued $250,000, $200,000, and $35,000, respectively, of senior subordinated convertible promissory notes to two members of the Company’s Board of Directors, two 5% shareholders,  and others.  The notes are convertible at the option of the holder at any time during the term of the note into common stock of the Company at an initial conversion price of $.65 per share, subject to adjustment for stock splits or subdivisions.  The notes are mandatorily convertible in the event of a Qualified Transaction (as defined in the notes) and the conversion price is adjustable to the lower of 75% of the price of a share of common stock sold in the Qualified Transaction or $.65. The notes bear interest at 7% per annum, are payable upon conversion or at maturity.  The notes mature November 1, 2014 and are unsecured. As additional consideration for the investors purchasing the notes, the Company issued the note holders fully vested three-year warrants to purchase an aggregate of 746,157 shares of the Company’s common stock at an exercise price equal to the lower of 120% of the conversion price or $.78 per share. The balance outstanding on the notes was $485,000 at December 31, 2013.
	The relative fair values of the warrants at the time of issuance, determined by management to be $92,283 in the aggregate, were recorded as a debt discount and will be amortized to interest expense over the term of the notes.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.78, expected life of three years; risk free interest rate of .58%; volatility of 63% and expected dividend yield of zero. Amortization of the debt discount was $875 for the year ended December 31, 2013 and $0 for the year ended December 31, 2012.
	In September 2013, the Company issued $50,000 of senior subordinated convertible promissory notes to an investor.  The notes are convertible at the option of the holder at any time during the term of the note into common stock of the Company at an initial conversion price of $.65 per share, subject to adjustment for stock splits or subdivisions.  The notes are mandatorily convertible in the event of a Qualified Transaction (as defined in the notes) and the conversion price is adjustable to the lower of 75% of the price of a share of common stock sold in the Qualified Transaction or $.65. The notes bear interest at 7% per annum, payable upon conversion or at maturity.  The notes mature in February 2015 and are unsecured. As additional consideration for the investor purchasing the notes, the Company issued the note holder fully vested three-year warrants to purchase an aggregate of 76,923 shares of the Company’s common stock at an exercise price equal to the lower of 120% of the conversion price or $.78 per share. The balance outstanding on the notes was $50,000 at December 31, 2013.
	The relative fair values of the warrants at the time of issuance, determined by management to be $9,000 in the aggregate, were recorded as a debt discount and will be amortized to interest expense over the term of the notes.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.78, expected life of five years; risk free interest rate of .63%; volatility of 63% and expected dividend yield of zero. Amortization of the debt discount was $1,566 for the year ended December 31, 2013 and $0 for the year ended December 31, 2012.
	In December 2013, the Company issued $50,000 of senior subordinated convertible promissory notes.  The notes are convertible at the option of the holder at any time during the term of the note into common stock of the Company at an initial conversion price of $.65 per share, subject to adjustment for stock splits or subdivisions.  The notes are mandatorily convertible in the event of a Qualified Transaction (as defined in the notes) and the conversion price is adjustable to the lower of 75% of the price of a share of common stock sold in the Qualified Transaction or $.65. The notes bear interest at 7% per annum, payable upon conversion or at maturity.  The notes mature in March 2015 and are unsecured. As additional consideration for the investor purchasing the notes, the Company issued the note holder fully vested three-year warrants to purchase an aggregate of 76,923 shares of the Company’s common stock at an exercise price equal to the lower of 120% of the conversion price or $.78 per share. The balance outstanding on the notes was $50,000 at December 31, 2013.
	The relative fair values of the warrants at the time of issuance, determined by management to be $9,000 in the aggregate, were recorded as a debt discount and will be amortized to interest expense over the term of the notes.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.78, expected life of five years; risk free interest rate of .63%; volatility of 63% and expected dividend yield of zero. Amortization of the debt discount was $155 for the year ended December 31, 2013 and $0 for the year ended December 31, 2012.
	The following table sets forth the future maturities of the Company’s convertible promissory notes net of unamortized discount at December 31, 2013:
		Year ended
		December 31,
		2014			947,987
		2015			328,388
		Total		$	1,276,375

CAPITAL_LEASE_OBLIGATIONS_RELA

CAPITAL LEASE OBLIGATIONS (RELATED PARTY)	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
CAPITAL LEASE OBLIGATIONS (RELATED PARTY)	'
	NOTE 7.	CAPITAL LEASE OBLIGATIONS (RELATED PARTY)
	Capital lease obligations (related party)  consisted of the following at December 31:
			2013			2012
	$199,610 capital lease obligation on equipment. The lease bears interest at 9.65%, is payable monthly in principal and interest installments of $2,704 and matures in May 2018.		$	53,916		$	134,827
	$69,200 capital lease obligation on equipment. The lease bore interest at 14.95%, was payable monthly in principal and interest installments of $1,644 and matured in May 2013.  In April, 2013, the Company purchased the assets from the related party lessor.			-			7,920
	$57,750 capital lease obligation on equipment. The lease bore interest at 9.15%, was payable monthly in principal and interest installments of $1,203 and matured in May 2013. In April 2013, the Company purchased the assets from the related party lessor.			-			7,029
	$72,375 capital lease obligation on equipment. The lease bore interest at 9.11%, was payable monthly in principal and interest installments of $2,123 and matured in April 2014. In April 2013, the Company purchased the assets from the related party lessor.			-			21,758
	Total capital lease obligations			53,916			171,534
	Less current portion			(10,286	)		(50,574	)
	Long-term portion		$	43,630		$	120,960
	The future minimum capital lease payments are as follows for the years ending December 31:
	2014		$	15,041
	2015			15,041
	2016			15,041
	2017			15,041
	2018			6,267
	Total minimum lease payments			66,431
	Less amount representing interest			(12,515	)
	Present value of minimum lease payments			53,916
	Less current portion			(10,286	)
	Long-term portion		$	43,630

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	NOTE 8.	RELATED PARTY TRANSACTIONS
	Management Services Agreement
	The Company and William Kirby D.O., Inc. operate under a management agreement entered into effective January 1, 2010, whereby the Company provides technical, management, administrative, marketing, support services and equipment to the sites where William Kirby D.O., Inc. provides or supervises tattoo removal services.  The agreement covers four clinics in southern California operated by the Company.  The Company had a $0 and $189,484 receivable due from William Kirby D.O., Inc. at December 31, 2013 and December 31, 2012, respectively.
	Pursuant to the Management Services Agreement, the Company provides certain non-medical management, administrative, marketing and support services to the clinics  where William Kirby, D.O., Inc. provides or supervises laser tattoo and hair removal services, which such services include employment of all non-licensed administrative personnel including an on-site manager and receptionist for each site and all support personnel such as accounting, information technology, human resources, purchasing and maintenance.  The Company also provides certain supplies, furniture and equipment used at the clinics.  The Company is also responsible for identifying and leasing the clinic locations and paying all rent, utilities and maintenance costs related thereto.  Under the Management Services Agreement, the Company also arranges third party marketing and advertising for the clinics.
	Medical Director Agreement
	Effective January 1, 2010, the Company entered into a Medical Director Agreement with William Kirby, D.O., Inc. and Dr. Kirby, under which the Company receives administrative, consultative and strategic services from William Kirby, D.O.  The initial term of the agreement is for five years, to be followed by automatic renewal terms of five years each.  The agreement provides for an annual payment of $250,000 to William Kirby, D.O. for these services. The Company’s unpaid current obligation under the Medical Director Agreement was $20,833 and $0 at December 31, 2013 and 2012, respectively. The unpaid amounts are included in related party payables in the accompanying consolidated balance sheets.
	Lease Guarantees
	William Kirby, D.O., Inc. was the named lessee under the lease for the clinic located in Encino, California.  Dr. Kirby personally guaranteed the lessee’s obligations under the Beverly Hills, Encino and Irvine, California leases. The Company and landlord amended the Beverly Hills, California lease in February 2013. The amendment extended the term by five years and released Dr. Kirby’s guarantee obligations. The Encino lease was terminated as of February 28, 2013 and the operations moved to a new location.  On July 21, 2011, the Company transferred its operations from the clinic located in Irvine, California to a clinic located in Santa Ana, California.  William Kirby, D.O., Inc. was the named lessee under the lease for the clinic located in Irvine, California, and Dr. Kirby personally guaranteed the lessee’s obligations under such lease. The Company continues to occupy the space in Irvine, where it operates a call center and maintains administrative offices.  The Company (or one of its wholly-owned subsidiaries) is the named lessee under the lease for all of its clinic leases.
	Dr. Kirby also guaranteed certain of the Company’s equipment leases until they were refinanced in June 2008.  The IPL devices currently used in three of the Company’s clinics are owned or leased by William Kirby, D.O., Inc. pursuant to various capitalized lease and/finance agreements with third party financing sources.  In addition, under the Management Services Agreement, the Company has the right, at any time, to purchase the equipment from William Kirby, D.O., Inc. at a purchase price of the amount outstanding, if any, under the applicable financing agreement.  The Company has accounted for these leases as capital leases based on the agreement terms.
	Shareholders Agreement
	Effective January 1, 2010, the Company entered into a Shareholders Agreement with William Kirby, D.O., Inc. and Dr. Kirby, pursuant to which, upon the occurrence of certain triggering events described below, Dr. Kirby is required to transfer his interest in William Kirby, D.O., Inc. to another licensed person or entity approved by the Company. Such triggering events include but are not limited to (i) the death or incapacity of Dr. Kirby, (ii) the loss of Dr. Kirby’s medical license, (iii) a breach of the obligations of William Kirby, D.O., Inc. and/or Dr. Kirby under the Amended and Restated Management Services Agreement or the Medical Director Agreement, (iv) the voluntary or involuntary transfer of Dr. Kirby’s interest in William Kirby, D.O., Inc., or (v) termination of the Amended and Restated Management Services Agreement in certain circumstances.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
EQUITY	'
	NOTE 9.	EQUITY
	Common Stock
	In March 2012, the Company sold 606,610 shares of common stock in a private placement for aggregate gross proceeds of $297,240.  Of the shares sold, 337,428 were sold to members of the Company’s management or board of directors and other Company affiliates, representing gross proceeds of $165,340.  In July 2012, the Company sold 1,580,613 shares of common stock in a private placement for aggregate gross proceeds of $774,500.  In August 2012, the Company sold 444,693 shares of common stock in a private placement for aggregate gross proceeds of $217,899.    In September 2012, the Company sold 266,225 shares of common stock in a private placement for aggregate gross proceeds of $130,450.  In October 2012, the Company sold 597,960 shares of common stock in a private placement for aggregate gross proceeds of $293,001 and issued 87,930 shares of common stock in exchange for services.
	In January 2013, the Company issued 35,700 shares of common stock to an employee pursuant to the exercise of a non-qualified stock option.  The Company received gross proceeds of approximately $17,500 in connection with the option exercise.  In March 2013, the Company sold 136,365 shares of common stock in a private placement for aggregate gross proceeds of approximately $75,000 and issued 423,061 shares of common stock valued at $.49 per share in exchange for services provided to the Company including an aggregate of 270,000 shares of common stock issued to the Company’s three independent directors as compensation for serving in such capacity and 153,061 shares issued to a consultant in connection with brand development.
	In April 2013, the Company sold 90,910 shares of common stock in a private placement for aggregate gross proceeds of approximately $50,000. In May 2013, the Company issued 145,455 shares of common stock valued at $.49 per share in exchange for consulting services provided to the Company.
	In December 2013, the Company issued 13,636 shares of common stock valued at $.49 per share in exchange for consulting services provided to the Company and issued 125,000 shares of common stock to a lender in connection with a line of credit. Also in December 2013, the Company issued 5,300 shares of its common stock to non-executive employees as additional compensation.
	Stock Options
	In April 2011, the Company’s board of directors adopted the Dr. Tattoff, Inc. Long-Term Incentive Plan for the purpose of granting incentive awards, including equity awards such as stock options or restricted stock, to certain officers, employees, directors, consultants and other service providers of our Company, to provide such recipients with additional incentives to enhance the value of our Company and encourage stock ownership. Under the Long-Term Incentive Plan, we can grant incentive and nonqualified options to purchase shares of our common stock, stock appreciation rights, other stock-based awards, which are settled in either cash or shares of our common stock and are determined by reference to shares of our stock (such as grants of restricted common stock, grants of rights to receive stock in the future or dividend equivalent rights) and cash performance awards, which are settled in cash and are not determined by reference to shares of our common stock.
	In March 2012, the Company granted 62,500 non-qualified stock options to an employee of William Kirby, D.O., Inc., vesting over four years with an exercise price of $.49.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock option approximated $18,000 on its issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 1.19%; volatility of 72%; and expected dividend yield of zero.
	In May 2012, two members of the Board of Directors each exercised an option to purchase 10,714 shares of Company common stock at a purchase price of $.3687 per share. The Company received aggregate proceeds of $7,900.
	In July 2012, the Company granted 35,700 non-qualified stock options to a consultant, vesting over four months with an exercise price of $.49.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock option approximated $12,200 on its issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 0.60%; volatility of 73%; and expected dividend yield of zero.
	In September 2012, the Company granted 25,000 incentive stock options to an employee, vesting over five years with an exercise price of $.49.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock option approximated $7,300 on its issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 0.67%; volatility of 73%; and expected dividend yield of zero.
	In November 2012, the Company granted 5,000 non-qualified options to a consultant, vesting over five years with an exercise price of $.49.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock option approximated $1,500 on its issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 0.63%; volatility of 73%; and expected dividend yield of zero.
	In November 2012, the Company granted 21,824 incentive options to employees of the Company and 10,337 non-qualified options to employees of William Kirby, D.O., Inc., vesting immediately with an exercise price of $.49.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $9,400 on their issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 0.63%; volatility of 73%; and expected dividend yield of zero.
	In January 2013, the Company granted 61,225 incentive stock options to an employee as part of his compensation package, vesting over twelve months with an exercise price of $.49.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock option approximated $17,300 on its issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 0.67%; volatility of 73%; and expected dividend yield of zero.
	In March 2013, the Company granted 24,041 incentive options to executive officers, 13,264 incentive options to other employees of the Company and 6,517 non-qualified options to employees of William Kirby, D.O., Inc., vesting immediately with an exercise price of $.49 as consideration for their agreement to defer compensation.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $14,000 on their issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 0.63%; volatility of 73%; and expected dividend yield of zero.  Also in March 2013, the Company granted 20,000 non-qualified options to each of the three independent members of its Board of Directors, vesting immediately and 45,000 options to each of the three independent members of its Board of Directors vesting 50% immediately and 25% on each the first and second anniversary of the grant date, with an exercise price of $.49 per share as compensation for serving on the Company’s Board of Directors.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $52,000 on their issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 0.63%; volatility of 73%; and expected dividend yield of zero.  Also in March 2013, the Company granted 10,000 non-qualified options to each of five members of its medical advisory board, with 25% vesting immediately and 25% vesting on each of the first, second and third anniversary of the grant date with an exercise price of $.49 per share.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $13,400 on their issuance date. Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 0.63%; volatility of 73%; and expected dividend yield of zero.   Also in March 2013, the Company granted 10,000 non-qualified options to each of five members of its medical advisory board, vesting 25% on each of the first through fourth anniversary of the grant date with an exercise price of $.55 per share.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $13,400 on their issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.49; expected life of five years; risk-free interest rate of 0.63%; volatility of 73%; and expected dividend yield of zero.
	In June 2013, the Company granted 212,413 incentive stock options to an employee as part of his compensation package, vesting over a four year period with an exercise price of $.55.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock option approximated $53,200 on its issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.55, expected life of five years; risk-free interest rate of 1.07%; volatility of 64%; and expected dividend yield of zero.
	In June 2013, the Company granted 10,000 non-qualified options to a new member of its medical advisory board, vesting 25% on each of the first through fourth anniversary of the grant date with an exercise price of $.55 per share.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $2,503 on their issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.55, expected life of five years; risk-free interest rate of 1.07%; volatility of 64%; and expected dividend yield of zero.
	In July 2013, the Company granted 112,727 incentive options to two employees as part of their compensation packages, vesting over a four year period with an exercise price of $.55. As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $28,100 on the issuance date. Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.55, expected life of five years; risk-free interest rate of 1.42%; volatility of 63%; and expected dividend yield of zero.
	In October 2013, the Company granted 7,327 incentive options to executive officers, 2,513 incentive options to other employees of the Company and 6,088 non-qualified options to William Kirby, D.O., vesting immediately with an exercise price of $.55 as consideration for their agreement to defer compensation.  As determined by management using the Black-Scholes option-pricing model, the estimated fair value of the aforementioned stock options approximated $3,900 on their issuance date.  Such estimate was based on the following assumptions: value of one common share of $0.49; strike price of $0.55; expected life of five years; risk-free interest rate of 1.41%; volatility of 63%; and expected dividend yield of zero.
	The Company recognized compensation expense of approximately $136,000 in 2013 and $71,000 in 2012 related to the options and grants, which is included in general and administrative expenses in the accompanying consolidated statements of operations.
	The following table summarizes stock option activity for the year ended December 31, 2013:
			Number				Weighted			Weighted
			of Options				Average Exercise			Average
							Price per Share			Grant-Date
										Fair Value
										per Share
	Outstanding at December 31, 2012			1,048,351			$	0.39		$	0.39
	Granted			750,845				0.52			0.44
	Exercised			(35,700	)			0.49			0.49
	Forfeited or Expired			(223,094	)			0.38			0.38
	Outstanding at December 31, 2013			1,540,402			$	0.45		$	0.44
	Exercisable at December 31, 2013			753,609			$	0.44		$	0.43
	Vested and expected to vest at December 31, 2013			1,540,402			$	0.45		$	0.44
	The aggregate intrinsic value of options exercised during the twelve months ended December 31, 2013 was $0. The aggregate intrinsic value of outstanding options was approximately $62,000 at December 31, 2013.
	Warrants
	In connection with the sale of common stock in a private placement in March 2012, the Company issued fully vested five-year warrants to purchase 303,305 shares of the Company’s common stock at a purchase price of $.595 per share.  The warrants expire on April 2, 2017. Warrants to purchase 168,714 shares were issued to members of management or board of directors and their affiliates in connection with their participation in the private placement.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of 1.03%; volatility of 70% and expected dividend yield of zero.  The net proceeds on the sale of common stock were allocated between the estimated fair value of the warrants at issuance of $79,500 and the common stock sold in the offering. The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets.
	In connection with issuance of the secured senior subordinated convertible notes in a private placement in May 2012, the Company issued fully vested five-year warrants to purchase 250,000 shares of the Company’s common stock at a purchase price of $.75 per share. The warrants expire on May 31, 2017. Warrants to purchase 250,000 shares were issued to members of management or board of directors and their affiliates in connection with their participation in the private placement. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.75, expected life of five years; risk free interest rate of .72%; volatility of 72% and expected dividend yield of zero. The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of $60,100 and the convertible notes issues in the offering. The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets.
	In connection with the sale of common stock in a private placement in July 2012, the Company issued fully vested five-year warrants to purchase 790,307 shares of the Company’s common stock at a purchase price of $.595 per share.  The warrants expire on July 31, 2017.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of .60%; volatility of 72% and expected dividend yield of zero.  The net proceeds on the sale of common stock were allocated between the estimated fair value of the warrants at issuance of $210,800 and the common stock sold in the offering. The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets.
	In connection with the sale of common stock in a private placement in August 2012, the Company issued fully vested five-year warrants to purchase 222,346 shares of the Company’s common stock at a purchase price of $.595 per share.  The warrants expire on August 31, 2017.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of .59%; volatility of 72% and expected dividend yield of zero.  The net proceeds on the sale of common stock were allocated between the estimated fair value of the warrants at issuance of $59,300 and the common stock sold in the offering. The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets.
	In connection with issuance of the secured senior subordinated convertible notes in a private placement in August 2012, the Company issued fully vested five-year warrants to purchase 318,750 shares of the Company’s common stock at a purchase price of $.75 per share. The warrants expire on August 31, 2017. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.75, expected life of five years; risk free interest rate of .51%; volatility of 72% and expected dividend yield of zero. The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of $58,650 and the convertible notes issues in the offering. The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets.
	In August 2012 the Company issued fully vested five-year warrants to purchase 400,000 shares of the Company’s common stock at a purchase price of $.49 per share in exchange for consulting services to be delivered over a twelve month period.  The warrants expire on August 31, 2017.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of .62%; volatility of 72% and expected dividend yield of zero.  The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants at issuance of $114,800 was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets and the consulting expense included in general and administrative expense.
	In connection with the sale of common stock in a private placement in September 2012, the Company issued fully vested five-year warrants to purchase 133,113 shares of the Company’s common stock at a purchase price of $.595 per share.  The warrants expire on September 30, 2017.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of .62%; volatility of 72% and expected dividend yield of zero.  The net proceeds on the sale of common stock were allocated between the estimated fair value of the warrants at issuance of $35,500 and the common stock sold in the offering. The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets.
	In connection with issuance of the secured senior subordinated convertible notes in a private placement in September 2012, the Company issued fully vested five-year warrants to a member of its board of directors to purchase 62,500 shares of the Company’s common stock at a purchase price of $.75 per share. The warrants expire on September 30, 2017. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.75, expected life of five years; risk free interest rate of .62%; volatility of 72% and expected dividend yield of zero. The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of $9,350 and the convertible notes issues in the offering. The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets.
	In connection with the sale of common stock in a private placement and the issuance of common stock in exchange for services in October 2012, the Company issued fully vested five-year warrants to purchase 340,037 shares of the Company’s common stock at a purchase price of $.595 per share.  The warrants expire on October 30, 2017.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of .59%; volatility of 73% and expected dividend yield of zero.  The net proceeds on the sale of common stock were allocated between the estimated fair value of the warrants at issuance of $92,600 and the common stock sold in the offering. The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets.
	In connection with issuance of the secured senior subordinated convertible notes in a private placement in October 2012, the Company issued fully vested five-year warrants to purchase 109,275 shares of the Company’s common stock at a purchase price of $.75 per share. The warrants expire on October 30, 2017. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.75, expected life of five years; risk free interest rate of .72%; volatility of 72% and expected dividend yield of zero. The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of $20,125 and the convertible notes issues in the offering. The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets.
	In November 2012, the Company issued fully vested five-year warrants to a third party to purchase 20,000 shares of the Company’s common stock at a purchase price of $.49 per share.  The warrants were issued in exchange for services and expire on November 12, 2017.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of .63%; volatility of 73% and expected dividend yield of zero. The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value at issuance of $5,800 was recognized as “consulting services” and is included within “general and administrative” expenses on the accompanying consolidated statements of operations and “additional paid-in capital” on the accompanying consolidated balance sheets.
	In January 2013, the Company issued five-year warrants to purchase 30,613 shares of the Company’s common stock at a purchase price of $.595 per share to an employee as part of his compensation package.  The warrants vest on a monthly basis through January 1, 2014 at which time the warrant will be fully vested.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of .62%; volatility of 72% and expected dividend yield of zero.  The Company has analyzed these warrants and determined them to be equity instruments. Accordingly the estimated fair value at issuance of $8,200 was recognized as “compensation expense” and is included within “general and administrative” expenses on the consolidated statements of operations and “additional paid-in capital” on the consolidated balance sheets.
	In connection with issuance of the secured senior subordinated convertible notes in a private placement in January 2013, the Company issued fully vested five-year warrants to purchase 375,000 shares of the Company’s common stock at a purchase price of $.75 per share as additional consideration to the investors, including 250,000 warrant shares to two members of the Company’s Board of Directors.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.75, expected life of five years; risk free interest rate of .88%; volatility of 72% and expected dividend yield of zero.  The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of $89,500 and the convertible notes issued in the offering.  The Company has analyzed these warrants and determined them to be equity instruments.  Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the consolidated balance sheets.
	In connection with issuance of the tenant improvement secured loan in February 2013, the Company issued fully vested five-year warrants to purchase 218,750 shares of the Company’s common stock at a purchase price of $.60 per share as additional consideration to the investors, including 62,500 warrant shares to members of the Company’s Board of Directors and management.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.75, expected life of five years; risk free interest rate of .88%; volatility of 72% and expected dividend yield of zero.  The net proceeds on the issuance of the tenant improvement secured loan were allocated between the estimated fair value of the warrants at issuance of $65,700 and the notes issued in the offering.  The Company has analyzed these warrants and determined them to be equity instruments.  Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the consolidated balance sheets.
	In March 2013, the Company issued fully vested five-year warrants to purchase 76,530 shares of the Company’s common stock at a purchase price of $.595 per share to a service provider as additional consideration for services provided.  The warrant expires on January 15, 2018.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of .62%; volatility of 72% and expected dividend yield of zero.  The Company has analyzed these warrants and determined them to be equity instruments.  The estimated fair value at issuance of $20,500 was recognized as “consulting expense” and is included within “general and administrative” expenses on the consolidated statements of operations and “additional paid-in capital” on the consolidated balance sheets.
	In connection with the sale of common stock in a private placement in March 2013, the Company issued fully vested five-year warrants to purchase 102,274 shares of the Company’s common stock at a purchase price of $.65 per share as additional consideration to the investors.  The warrants expire on March 12, 2018. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of .88%; volatility of 72% and expected dividend yield of zero.  The net proceeds on the sale of common stock were allocated between the estimated fair value of the warrants at issuance of $26,000 and the common stock sold in the offering.  The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the consolidated balance sheets.
	In connection with the sale of common stock in a private placement in April 2013, the Company issued fully vested five-year warrants to purchase 68,183 shares of the Company’s common stock at a purchase price of $.65 per share as additional consideration to the investors.  The warrants expire on April 11, 2018. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of .74%; volatility of 64% and expected dividend yield of zero.  The net proceeds on the sale of common stock were allocated between the estimated fair value of the warrants at issuance of $15,600 and the common stock sold in the offering.  The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the consolidated balance sheets.
	In May 2013, the Company issued five-year warrants, vesting over one year, to purchase 34,090 shares of the Company’s common stock at a purchase price of $.65 per share to a service provider as additional consideration for services provided.  The warrant expires on May 16, 2018.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of .79%; volatility of 64% and expected dividend yield of zero.  The Company has analyzed these warrants and determined them to be equity instruments.  The estimated fair value at issuance of $7,811 was recognized as “consulting expense” and is included within “general and administrative” expenses on the consolidated statements of operations and “additional paid-in capital” on the consolidated balance sheets.
	In connection with issuance of the senior subordinated convertible notes in a private placement in May, June and July 2013, the Company issued fully vested five-year warrants to purchase 186,537 shares of the Company’s common stock at a purchase price of $.78 per share as additional consideration to the investors.  In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 25% of the number of conversion shares and the strike price adjusted to 120% of the conversion price. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.78, expected life of five years; risk free interest rate of 1.07%; volatility of 64% and expected dividend yield of zero.  The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of $36,250 and the convertible notes issued in the offering.  The Company has analyzed these warrants and determined them to be debt instruments.  Accordingly, the estimated fair value of the warrants was recognized as “warrant liability” on the consolidated balance sheets. The warrants were exchanged in December 2013 and had no value at December 31, 2013.
	In connection with the issuance of unsecured promissory notes in August 2013, the Company issued five-year warrants to purchase 120,000 shares of the Company’s common stock at a purchase price of $.60 per share as additional consideration to the note holders. The warrants expire on August 13, 2018. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.60, expected life of five years; risk free interest rate of 1.48%; volatility of 63% and expected dividend yield of zero.  The net proceeds on the unsecured promissory notes were allocated between the estimated fair value of the warrants at issuance of $28,700 and the notes issued.  The Company has analyzed these warrants and determined them to be equity instruments.  Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the consolidated balance sheets.
	In July 2013, the Company issued five-year warrants to purchase 84,545 shares of the Company’s common stock at a purchase price of $.65 per share to two employees as part of their compensation package.  The warrants vest on a monthly basis through July 2014 at which time the warrant will be fully vested.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of 1.41%; volatility of 63% and expected dividend yield of zero.  The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value at issuance of $19,400 was recognized as “compensation expense” and is included within “general and administrative” expenses on the consolidated statements of operations and “additional paid-in capital” on the consolidated balance sheets.
	In connection with the issuance of senior subordinated convertible notes in a private placement in September 2013, the Company issued fully vested three-year warrants to purchase 76,923 shares of the Company’s common stock at a purchase price of $.78 per share as additional consideration to the investor.  In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 25% of the number of conversion shares and the strike price adjusted to 120% of the conversion price. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.78, expected life of three years; risk free interest rate of .63%; volatility of 63% and expected dividend yield of zero.  The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of $10,900 and the convertible notes issued in the offering.  The Company has analyzed these warrants and determined them to be debt instruments.  Accordingly, the estimated fair value of the warrants was recognized as “warrant liability” on the consolidated balance sheets. The Company determined the fair value of the warrant liability to be $10,200 at December 31, 2013.
	In October 2013 the Company issued fully vested five-year warrants to purchase 450,000 shares of the Company’s common stock at a purchase price of $1.00 per share in exchange for consulting services to be delivered over a twelve month period.  The warrants expire on October 1, 2018.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of 1.41%; volatility of 63% and expected dividend yield of zero.  The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants at issuance of $80,300 was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets and the consulting expense included in general and administrative expense.
	In connection with the issuance of unsecured promissory notes in October 2013, the Company issued fully vested five-year warrants to purchase 200,000 shares of the Company’s common stock at a purchase price of $.60 per share as additional consideration to the note holder. The warrants expire on October 31, 2018. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.60, expected life of five years; risk free interest rate of 1.30%; volatility of 63% and expected dividend yield of zero.  The net proceeds on the unsecured promissory notes were allocated between the estimated fair value of the warrants at issuance of $38,000 and the notes issued.  The Company has analyzed these warrants and determined them to be equity instruments.  Accordingly, the estimated fair value of the warrants was recognized as “additional paid-in capital” on the consolidated balance sheets.
	In December 2013 the Company issued fully vested warrants to purchase 39,000 shares of the Company’s common stock at a purchase price of $.78 per share in exchange for services related to the Company’s new revolving loan facility. The warrants expire on December 2, 2016.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of three years; risk free interest rate of .58%; volatility of 63% and expected dividend yield of zero.  The Company has analyzed these warrants and determined them to be debt instruments. Accordingly, the estimated fair value of the warrants was recognized as “warrant liability” on the consolidated balance sheets and the expense will be amortized over the term of the revolving loan and included in interest expense. The Company determined the fair value of the warrant liability to be $4,300 at issuance and $5,400 at December 31, 2013.
	In December 2013, the Company exchanged 186,537 warrants that had been issued in connection with the issuance of the senior subordinated convertible notes in a private placement in May, June and July 2013 with new warrants. The number of shares of common stock that can be purchased by the warrant holder was increased to 746,157 and the term of the warrant was decreased from five to three years. In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 25% of the number of conversion shares and the strike price adjusted to 120% of the conversion price. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.78, expected life of two and one half years; risk free interest rate of .58%; volatility of 63% and expected dividend yield of zero.  The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of $91,400 and the convertible notes issued in the offering.  The Company has analyzed these warrants and determined them to be debt instruments.  Accordingly, the estimated fair value of the warrants was recognized as “warrant liability” on the consolidated balance sheets. The Company determined the fair value of the warrant liability to be $91,400 at December 31, 2013.
	In December 2013 the Company issued fully vested five-year warrants to purchase 115,240 shares of the Company’s common stock at a purchase price of $.60 per share in exchange for an extension on the due date of the Company’s tenant improvement secured loan.  The warrants expire on December 31, 2018.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of 1.73%; volatility of 63% and expected dividend yield of zero.  The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants at issuance of $27,700 was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets and the expense will be included in interest expense over the term of the loan extension.
In December 2013 the Company issued fully vested warrants to purchase 310,893 shares of the Company’s common stock at a purchase price of $.60 per share in exchange for an extension on the due date of the Company’s unsecured promissory notes.  The warrants expire on December 31, 2018.  The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, expected life of five years; risk free interest rate of 1.73%; volatility of 63% and expected dividend yield of zero.  The Company has analyzed these warrants and determined them to be equity instruments. Accordingly, the estimated fair value of the warrants at issuance of $74,800 was recognized as “additional paid-in capital” on the accompanying consolidated balance sheets and the expense will be included in interest expense over the term of the note extensions.
In connection with the issuance of senior subordinated convertible notes in a private placement in December 2013, the Company issued fully vested three year warrants to purchase 76,923 shares of the Company’s common stock at a purchase price of $.78 per share as additional consideration to the investor.  In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 100% of the number of conversion shares and the strike price adjusted to 120% of the conversion price. The Company estimated the fair value of the warrants issued based upon the application of the Black-Scholes option pricing model using the following assumptions: value of common share of $.49, strike price $.78, expected life of three years; risk free interest rate of .63%; volatility of 63% and expected dividend yield of zero.  The net proceeds on the issuance of the convertible notes were allocated between the estimated fair value of the warrants at issuance of $10,900 and the convertible notes issued in the offering.  The Company has analyzed these warrants and determined them to be debt instruments.  Accordingly, the estimated fair value of the warrants was recognized as “warrant liability” on the consolidated balance sheets. The Company determined the fair value of the warrant liability to be $10,900 at December 31, 2013.
The following tables summarize the warrant activity:
		Shares			Weighted				Weighted Average
					Average				Remaining Contractual
					Exercise				Life (in years)
					Price
Outstanding at January 1, 2012			269,558			$	1.28			2.9
Granted			2,949,633				0.62			4.6
Exercised			-				-			-
Expired or cancelled			-68,757				2.13			-
Exercisable at December 31, 2012			3,150,434			$	0.64			4.5
Granted			3,562,914				0.73			4
Exercised			-				-			-
Expired or cancelled			-204,933				0.93			-
Exercisable at December 31, 2013			6,508,415			$	0.62			3.8
Warrants Outstanding and Exercisable
Number of Shares		Range of			Expiration		Weighted
Under Warrants		Exercise			Date		Average
		Prices					Exercise
							Price
128,840		$	0.37		2015		$	0.37
915,651			.59-.78		2016			0.77
2,949,633			.49-.75		2017			0.62
2,514,291			.59-1.00		2018			0.71
6,508,415		$	.37-1.00				$	0.62

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 10.	COMMITMENTS AND CONTINGENCIES
	Legal Contingencies
	From time to time, the Company is involved in legal matters which arise in the normal course of business. Management believes that the final resolution of such matters will not have a material adverse effect on the Company’s financial position or results of operations.
	Operating Leases
	The Company leases its Irvine, California office from William Kirby, D.O., Inc., a related party.    The Company leases its clinics from unrelated third parties, which expire through 2020.   Lease agreements, in addition to base rentals, generally are subject to annual escalation provisions that range from 3% to 4% and options to renew ranging from 3 years to 5 years.
	The aggregate minimum future payments required on the operating leases are as follows for the years ending December 31:
	2014		$	635,811
	2015			665,821
	2016			678,707
	2017			501,659
	2018			213,531
	Thereafter			148,873
			$	2,844,402
	Rent expense relating to related party leases for the years ended December 31, 2013 and December 31, 2012 approximated $42,000 and $198,000, respectively.  Rent expense related to third party leases for the years ended December 31, 2013 and December 31, 2012 approximated $586,000 and $239,000, respectively.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	NOTE 11.	INCOME TAXES
	The Company accounts for income taxes under the provisions of ASC 740, which requires recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns.
	The components of the provision for income taxes for the years ended December 31, 2013 and 2012 is comprised of the following:
			2013			2012
	Current
	Federal		$	–		$	–
	State			800			800
				800			800
	Deferred
	Federal			–			–
	State			–			–
	Total		$	800		$	800
	The difference between income taxes at statutory rates and the amount presented in the consolidated financial statements is a result of the following for the years ended December 31, 2013 and 2012:
			2013			2012
	Computed expected income tax benefit at federal statutory rates			34%			34%
	Addition to (reduction in) income taxes resulting from:
	State income taxes, net of federal benefit			6%			6%
	Other			-%			-%
	Valuation allowance			(40%	)		(40%	)
	Total			0%			0%
	Deferred taxes arise because of temporary differences in the book and tax bases of certain assets and liabilities. Significant components of deferred taxes at December 31, 2013 and 2012 are set forth below:
			2013			2012
	Net operating loss carryforwards		$	4,286,000		$	3,150,000
	Other			708,000			209,000
	Less valuation allowance			(4,994,000	)		(3,359,000	)
	Net deferred tax assets		$	–		$	–
	The Company has federal tax net operating loss carryforwards of approximately $9,300,000 and $6,200,000, at December 31, 2013 and December 31, 2012, respectively, both of which will begin expiring in 2028.  The Company has California state tax net operating loss carryforwards of approximately $8,000,000 and $5,500,000, at December 31, 2013 and December 31, 2012, respectively, which will begin expiring in 2028.  The amount of net operating loss carry forward that can be used in any one year may be limited by significant changes in ownership as defined by section 382 of the Internal Revenue Code and similar state tax laws.
	In assessing the realizability of deferred tax assets, management considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.  Based upon the Company’s history of continuing operating losses, realization of its deferred tax assets does not meet the “more likely than not” criteria under ASC 740.  Accordingly, the Company has recorded a 100% valuation allowance to offset the net deferred tax assets at December 31, 2013 and 2012. For the years ended December 31, 2013 and 2012, the Company’s change in valuation allowance was approximately $1,635,000 and $1,081,000, respectively.
	The Company will recognize interest and penalties related to unrecognized tax benefits and penalties as income tax expense.  As of December 31, 2013, the Company has not recognized liabilities for penalties and interest as the Company does not have liabilities for unrecognized tax benefits.  The Company’s income tax returns are subject to examination by the taxing authorities, generally 3 years for federal and 4 years for state (California).

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 12.	SUBSEQUENT EVENTS
	Subsequent events have been evaluated through the date on which these financial statements have been issued.
	In February 2014, the Company closed its clinic in Sugar Land, Texas due to poor financial performance and directed its Sugar Land patients to the Company’s location near the Houston Galleria. In March 2014, the Company opened a new location in Frisco, Texas, a suburb of Dallas.  The Company relocated substantially all of the equipment from the Sugar Land location to other locations and is presently negotiating with the landlord of the Sugar Land clinic to terminate the lease or find a tenant to sublease the space.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying consolidated financial statements of Dr. Tattoff, Inc. and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid short-term investments with original maturity of three months or less to be cash equivalents.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company adopted the fair value measurement and disclosure requirements of ASC 820, Fair Value Measurements and Disclosure for financial assets and liabilities measured on a recurring basis.  ASC 820 defines fair value, establishes a framework for measuring fair value under GAAP and expands disclosures about fair value measurements.  This standard applies in situations where other accounting pronouncements either permit or require fair value measurements. ASC 820 does not require any new fair value measurements.
	Fair value is defined in ASC 820 as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The standard describes three levels of inputs that may be used to measure fair value:
	Level 1:	Quoted prices in active markets for identical or similar assets and liabilities.
	Level 2:	Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
	Level 3:	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s financial instruments include cash and cash equivalents, management fee due from related party, prepaid expenses and other current assets, other assets, accounts payable, related party payable, accrued expenses and other liabilities, deferred revenue, accrued compensation, capital lease obligations, convertible promissory notes, notes payable, and warrant liabilities.  The carrying amounts of management fee due from related party, prepaid expenses and other current assets, other assets, accounts payable, related party payable, accrued expenses and other liabilities, deferred revenue and accrued compensation approximate their fair values due to the short maturity of these instruments.  The carrying amounts of capital leases, convertible promissory notes, and notes payable approximates their fair value as these instruments earn or are charged interest based on prevailing rates. The fair value of warrants is measured using level 3 inputs.
Long-lived Assets	'
	Long-lived Assets
	Long-lived assets are reviewed for impairment in accordance with ASC No. 360 “Accounting for the Impairment or Disposal of Long-Lived Assets,” which requires impairment losses to be recorded on long-lived assets when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  For purposes of the impairment review, assets are reviewed on an asset-by-asset basis. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of each asset to future net cash flows on an undiscounted basis expected to be generated by such asset.  If such assets are considered to be impaired, the impairment to be recognized is measured by the amount which the carrying amount of the assets on an undiscounted basis exceeds the fair value of the assets.
	The major long-lived assets of the Company are the lasers and Intense Pulse Light, or IPL devices.  While the Company has sustained losses, the clinics where the lasers and IPL devices are located are either profitable or new and expected to be profitable.  As a result, recoverability of assets to be held and used is measured by a comparison of the carrying amount of each asset to future net cash flows on an undiscounted basis expected to be generated by such asset in each clinic.  There were no impairments of long-lived assets at December 31, 2013 and 2012.
Property and Equipment	'
	Property and Equipment
	Property and equipment is recorded at cost, less accumulated depreciation.  Depreciation is recorded using the straight-line method over the estimated useful lives of the related assets.  The Company uses the following estimated useful lives for computing depreciation expense: furniture and fixtures, 7 years; medical equipment, 7 years; other equipment, 3 to 5 years.  Amortization of leasehold improvements is recorded using the straight-line method based on the lesser of the useful life of the improvement or the lease term, which is typically five years or less.
Debt and Other Financial Instruments	'
	Debt and Other Financial Instruments
	Debt/Equity Instruments Issued with Warrants
	The Company estimates the relative fair values of the debt and warrants, and allocates the proceeds pro-rata based on these values. The allocation of proceeds to the warrants results in the debt instrument being recorded at a discount from the face amount of the debt and the value allocated to the warrant is recorded to additional paid-in capital.
	The Company reviews the terms of convertible financial instruments it issues to determine whether there are embedded derivative instruments, including the conversion option that may be required to be bifurcated and accounted for separately as a derivative financial instrument.  In circumstances where the convertible instrument contains more than one embedded derivative, including the conversion option that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	When the convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds from the convertible host instruments are first allocated to the bifurcated derivative instruments.  The remaining proceeds, if any, are then allocated to the convertible instruments themselves, resulting in those instruments being recorded at a discount from their face value.
	Derivative Financial Instruments
	Derivative instruments are initially recorded at estimated fair value and are then revalued at each reporting date with changes in the estimated fair value reported as charges or credits to income.
Revenue Recognition	'
	Revenue Recognition
	Currently, the majority of the Company’s revenues are derived from management services provided to William Kirby D.O., Inc., a related party, for our non-owned clinics.  The Company provides nonmedical services and facilities based on contractual prices established in advance that extend continuously over a set time for a fixed percentage of the contracting physician’s gross revenues (as defined in the Management Services Agreement - See Note 8, “Related Party Transactions”) with no upfront fees paid by William Kirby D.O., Inc.  The management services agreement with William Kirby D.O., Inc. covers all of the Company’s California locations.
	Under the management service agreement with William Kirby D.O., Inc., there is no right to refund or rejection of services.  The Company recognizes revenue when the following criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  Management services fees are paid by the contracting physician to the Company on a bi-weekly basis as earned, which is when the Company has substantially performed management services pursuant to the terms of the management services agreement with William Kirby D.O., Inc.
	The Company operates the Dallas, Houston, Atlanta and Phoenix locations directly, not pursuant to a management services agreement with a physician. Accordingly, patients contract with the Company and pay for the services they receive directly to the Company.  The Company recognizes revenue when the following criteria of revenue recognition are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.  The Company requires payment at the time of the patient visit or in advance of the visit by those patients purchasing packages of treatments. Payments by patients made in advance of service delivery are recorded as “deferred revenue” on the accompanying consolidated balance sheets and amounted to approximately $1,114,000 at December 31, 2013 and $503,000 at December 31, 2012.
	Patients who purchase a package of tattoo removal services at clinics the Company operates directly are eligible to participate in the Company’s tattoo removal guarantee program.  Pursuant to the guarantee program, if the tattoo is not fully removed within the recommended number of treatments, the Company will continue to provide additional treatments, consistent with the Company’s medical protocols, for a period of up to one year following the date of the last paid treatment.  The Company estimates the cost of the guarantee program based on historical usage and the average cost of treatments.  The cost of the program is accrued on a per visit basis as visits occur and is included in clinic operating expense on the accompanying consolidated statements of operations.  The Company recognized accrued expense of approximately $77,000 and $37,000 as of December 31, 2013 and December 31, 2012, respectively, related to the guarantee program, and this is included in the accrued expenses and other liabilities in the accompanying consolidated balance sheets.  Patients who purchase a package of services and experience complete removal prior to completion of the package are eligible for a refund for the unused portion of the package.  The Company recognizes refunds, which have been immaterial in amount, as a reduction in revenue as incurred.  Patients who receive services in clinics operated under the management services agreement with William Kirby, D.O., Inc. are eligible for similar programs, which may reduce the management fee that the Company receives.
Advertising Costs	'
	Advertising Costs
	Advertising costs are expensed as incurred.  For the years ended December 31, 2013 and 2012, advertising expense was approximately $570,000 and $359,000, respectively, and is included in marketing and advertising in the accompanying consolidated statement of operations.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 740 “Income taxes.”  Under ASC 740, deferred income taxes are recognized to reflect the tax consequences in future years for the differences between the amounts of assets and liabilities recognized for financial reporting purposes and such amounts recognized for income tax reporting purposes using enacted tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided to reduce net deferred tax assets to amounts that are more likely than not to be realized.
	The Company has incurred tax net operating losses since inception and, accordingly, has a deferred tax asset related to such tax net operating loss carryforwards.  The Company has provided a 100% valuation allowance on such deferred tax asset at December 31, 2013 and 2012 (See Note 11, “Income Taxes”).
	The Company accounts for uncertainty in income taxes in accordance with ASC 740-10, which prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.  ASC 740-10 also provides guidance on the measurement, derecognition, classification and disclosure of tax positions, as well as the accounting for related interest and penalties.  The Company’s policy is to recognize interest and penalties that would be assessed in relation to the settlement value of unrecognized tax benefits as a component of income tax expense.  The Company has recognized no tax related interest or penalties since the adoption of ASC 740-10.  As of December 31, 2013, the open tax years of the Company were 2009 to 2013.
Earnings Per Share	'
	Earnings Per Share
	Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period.  Diluted earnings per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company.  In computing diluted earnings per share, the treasury stock method assumes that outstanding options are exercised and the proceeds are used to purchase common stock at the average market price during the period.  Options will have a dilutive effect under the treasury stock method only when the Company reports net income and the average market price of the common stock during the period exceeds the exercise price of the options.  Options, warrants and conversions of convertible debt instruments were not included in computing diluted earnings per share for the years ended December 31, 2013 and 2012, respectively because their effects were antidilutive.
	The following table illustrates the computation of basic and diluted earnings per share:
			2013			2012
	Net loss available to common stockholders (numerator)		$	(4,300,543	)	$	(2,839,796	)
	Weighted average shares outstanding (denominator)			18,743,738			15,983,905
	Basic and diluted EPS		$	(.23	)	$	(.18	)
	Basic and diluted EPS are the same for all periods presented as the impact of all potentially dilutive securities were anti-dilutive. The following potentially dilutive securities were not included in the computation of diluted EPS because to do so would have been anti-dilutive for the periods presented.
			2013			2012
	Warrants			6,508,415			3,150,434
	Common stock options			1,540,402			1,048,351
	Convertible promissory notes			2,387,510			987,500
				10,436,327			5,186,285
Accounting for Common Stock Options	'
	Accounting for Common Stock Options
	The Company measures stock-based compensation expense at the grant date, based on the fair value of the award, and recognizes the expense over the employee’s requisite service (vesting) period using the straight-line method.  The measurement of stock-based compensation expense is based on several criteria including, but not limited to, the valuation model used and associated input factors, such as expected term of the award, stock price volatility, risk free interest rate and forfeiture rate.  Certain of these inputs are subjective to some degree and are determined based in part on management’s judgment.  The Company recognizes the compensation expense on a straight-line basis for its graded vesting awards.  Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.  However, the cumulative compensation expense recognized at any point in time must at least equal the portion of the grant-date fair value of the award that is vested at that date. As used in this context, the term “forfeitures” is distinct from “cancellations” or “expirations”, and refers only to the unvested portion of the surrendered equity awards.
Deferred Rent	'
	Deferred Rent
	The Company currently leases all of its locations under leases classified as operating leases.  Minimum base rent for these operating leases, which generally have escalating rentals over the term of the lease is recorded on a straight-line basis over the lease term.  As such, an equal amount of rent expense is attributed to each period during the term of the lease regardless of when actual payments occur.  Lease terms begin on the inception date and include option periods only where such renewals are imminent and assured.  The difference between rent expense and actual cash payments is classified as “deferred rent” in the accompanying consolidated balance sheets and approximated $252,000 and $105,000 at December 31, 2013 and 2012, respectively.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.  Actual results could differ from those estimates.  Significant estimates include those related to the realization of long-lived assets, deferred income tax asset valuation allowances, and the valuation of equity instruments issued.
Concentrations	'
	Concentrations
	Financial instruments that subject the Company to credit risk consist primarily of cash and revenues.  The Company’s cash and cash equivalents are maintained at financial institutions in the United States.  These accounts are insured by the Federal Deposit Insurance Corporation (“FDIC”).  At times, such balances may be in excess of the amounts insured by the FDIC.  The Company has not experienced any losses on such accounts and believes it is not exposed to any significant credit risks on its cash and cash equivalents.
	A significant portion of the Company’s revenues in 2013 and 2012 were derived from a management services agreement relating to the Company’s California clinics pursuant to a management services agreement with William Kirby D.O., Inc.  If the Company’s management services agreement is terminated for any reason or William Kirby, D.O., Inc. defaults on its obligations thereunder, the Company’s operating results, cash flows and financial performance may be adversely affected and the Company may need to negotiate and enter into a new agreement with a qualified physician.  Although the Company’s management services agreement provides the Company with the right to approve a replacement contracting physician upon termination or default, the Company can give no assurance that it will be able to expeditiously identify and contract with a qualified replacement physician on commercially reasonable terms or at all.  The termination of the Company’s management services arrangement could have a material adverse effect on the Company’s consolidated financial condition, cash flows and results of operations.
Significant Recent Accounting Pronouncements	'
	Significant Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board issued Accounting Standards Update No. 2013-11, Income Taxes (Topic 740) (“ASU 2013-11”), which requires the financial statement presentation of an unrecognized tax benefit in a particular jurisdiction, or a portion thereof, as a reduction to a deferred tax asset for a net operating loss (“NOL”) carryforward, a similar tax loss, or a tax credit carryforward, unless the uncertain tax position is not available to reduce, or would not be used to reduce, the NOL or carryforward under the tax law in the same jurisdiction; otherwise, the unrecognized tax benefit should be presented as a gross liability and should not be combined with a deferred tax asset. ASU 2013-11 is effective for interim and annual periods beginning after December 15, 2013. The Company does not expect that this new guidance will have a significant impact on the Company’s consolidated financial position, results of operations or cash flows.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants (“AICPA”), and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

ORGANIZATION_AND_NATURE_OF_OPE1

ORGANIZATION AND NATURE OF OPERATIONS (Tables)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'
Schedule of carrying amount and classification of assets and liabilities	'
		December 31,
		2013		2012
	Current Assets
	Management fee due from related party	$	-	$	189,484
	Non-Current Assets
	Assets under capital lease, net		-		39,064
	Current Liabilities
	Related party payables		23,622		-
	Capital lease obligations, current portion		10,286		50,574
	Long-Term Liabilities
	Capital lease obligations, net of current portion		43,630		120,960

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of computation of basic and diluted earnings per share	'
		2013			2012
	Net loss available to common stockholders (numerator)	$	(4,300,543	)	$	(2,839,796	)
	Weighted average shares outstanding (denominator)		18,743,738			15,983,905
	Basic and diluted EPS	$	(.23	)	$	(.18	)
Schedule of dilutive securities excluded from the computation of diluted EPS	'
		2013			2012
	Warrants		6,508,415			3,150,434
	Common stock options		1,540,402			1,048,351
	Convertible promissory notes		2,387,510			987,500
			10,436,327			5,186,285

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of property and equipment	'
		2013			2012
	Equipment	$	1,824,871		$	1,382,005
	Furniture and fixtures		136,426			93,129
	Leasehold improvements		1,217,223			803,335
			3,178,520			2,278,469
	Less accumulated depreciation and amortization		(1,128,233	)		(967,160	)
		$	2,050,287		$	1,311,309

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2013
Notes Payable [Abstract]	'
Schedule of components of notes payable	'
			2013			2012
	Financed insurance premiums		$	-		$	4,510
	Equipment promissory notes			674,474			313,268
	Tenant improvement secured loans			100,000			-
	Unsecured promissory notes			300,000			-
				1,074,474			317,778
	Less unamortized discount			(102,487	)		-
	Less current portion (net of unamortized discounts)			(716,531	)		(195,819	)
			$	255,456		$	121,959
Schedule of future maturities of the company's outstanding notes payable	'
		Year ended
		December 31,
		2014		$	716,531
		2015			250,016
		2016			5,440
		Total		$	971,987

CONVERTIBLE_PROMISSORY_NOTES_T

CONVERTIBLE PROMISSORY NOTES (Tables)	12 Months Ended
	Dec. 31, 2013
Convertible Promissory Notes [Abstract]	'
Schedule of convertible promissory notes payable	'
			2013			2012
	Secured senior subordinated convertible promissory notes		$	892,500		$	592,500
	Senior subordinated convertible promissory notes			585,000			-
				1,477,500			592,500
	Less unamortized discount			(201,125	)		(139,721	)
	Less current portion (net of unamortized discounts)			(947,987	)		-
			$	328,388		$	452,779
Schedule of future maturities of the Company's outstanding convertible promissory notes	'
		Year ended
		December 31,
		2014			947,987
		2015			328,388
		Total		$	1,276,375

CAPITAL_LEASE_OBLIGATIONS_RELA1

CAPITAL LEASE OBLIGATIONS (RELATED PARTY) (Tables)	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Schedule of components of capital lease obligations	'
		2013			2012
	$199,610 capital lease obligation on equipment. The lease bears interest at 9.65%, is payable monthly in principal and interest installments of $2,704 and matures in May 2018.	$	53,916		$	134,827
	$69,200 capital lease obligation on equipment. The lease bore interest at 14.95%, was payable monthly in principal and interest installments of $1,644 and matured in May 2013.  In April, 2013, the Company purchased the assets from the related party lessor.		-			7,920
	$57,750 capital lease obligation on equipment. The lease bore interest at 9.15%, was payable monthly in principal and interest installments of $1,203 and matured in May 2013. In April 2013, the Company purchased the assets from the related party lessor.		-			7,029
	$72,375 capital lease obligation on equipment. The lease bore interest at 9.11%, was payable monthly in principal and interest installments of $2,123 and matured in April 2014. In April 2013, the Company purchased the assets from the related party lessor.		-			21,758
	Total capital lease obligations		53,916			171,534
	Less current portion		(10,286	)		(50,574	)
	Long-term portion	$	43,630		$	120,960
Schedule of future minimum capital lease payments	'
	2014	$	15,041
	2015		15,041
	2016		15,041
	2017		15,041
	2018		6,267
	Total minimum lease payments		66,431
	Less amount representing interest		(12,515	)
	Present value of minimum lease payments		53,916
	Less current portion		(10,286	)
	Long-term portion	$	43,630

EQUITY_Tables

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Schedule of company's stock option activity	'
		Number				Weighted			Weighted
		of Options				Average Exercise			Average
						Price per Share			Grant-Date
									Fair Value
									per Share
	Outstanding at December 31, 2012		1,048,351			$	0.39		$	0.39
	Granted		750,845				0.52			0.44
	Exercised		(35,700	)			0.49			0.49
	Forfeited or Expired		(223,094	)			0.38			0.38
	Outstanding at December 31, 2013		1,540,402			$	0.45		$	0.44
	Exercisable at December 31, 2013		753,609			$	0.44		$	0.43
	Vested and expected to vest at December 31, 2013		1,540,402			$	0.45		$	0.44
Schedule of company's warrant activity	'
		Shares			Weighted				Weighted Average
					Average				Remaining Contractual
					Exercise				Life (in years)
					Price
	Outstanding at January 1, 2012		269,558			$	1.28			2.9
	Granted		2,949,633				0.62			4.6
	Exercised		-				-			-
	Expired or cancelled		-68,757				2.13			-
	Exercisable at December 31, 2012		3,150,434			$	0.64			4.5
	Granted		3,562,914				0.73			4
	Exercised		-				-			-
	Expired or cancelled		-204,933				0.93			-
	Exercisable at December 31, 2013		6,508,415			$	0.62			3.8
Schedule of stockholders equity warrants or rights outstanding and exercisable	'
	Warrants Outstanding and Exercisable
	Number of Shares	Range of			Expiration		Weighted
	Under Warrants	Exercise			Date		Average
		Prices					Exercise
							Price
	128,840	$	0.37		2015		$	0.37
	915,651		.59-.78		2016			0.77
	2,949,633		.49-.75		2017			0.62
	2,514,291		.59-1.00		2018			0.71
	6,508,415	$	.37-1.00				$	0.62

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of aggregate minimum future payments required on the operating leases	'
	2014	$	635,811
	2015		665,821
	2016		678,707
	2017		501,659
	2018		213,531
	Thereafter		148,873
		$	2,844,402

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of provision for income taxes	'
		2013			2012
	Current
	Federal	$	–		$	–
	State		800			800
			800			800
	Deferred
	Federal		–			–
	State		–			–
	Total	$	800		$	800
Schedule of income tax rate reconciliation	'
		2013			2012
	Computed expected income tax benefit at federal statutory rates		34%			34%
	Addition to (reduction in) income taxes resulting from:
	State income taxes, net of federal benefit		6%			6%
	Other		-%			-%
	Valuation allowance		(40%	)		(40%	)
	Total		0%			0%
Schedule of deferred tax assets and liabilities	'
		2013			2012
	Net operating loss carryforwards	$	4,286,000		$	3,150,000
	Other		708,000			209,000
	Less valuation allowance		(4,994,000	)		(3,359,000	)
	Net deferred tax assets	$	–		$	–

ORGANIZATION_AND_NATURE_OF_OPE2

ORGANIZATION AND NATURE OF OPERATIONS - Summary of carrying amount and classification of assets and liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current Assets	'	'
Management fee due from related party	'	$189,484
Current Liabilities	'	'
Related party payables	23,622	'
Capital lease obligations, current portion	10,286	50,574
Long-Term Liabilities	'	'
Capital lease obligations, net of current portion	43,630	120,960
William Kirby, D.O., Inc	'	'
Current Assets	'	'
Management fee due from related party	'	189,484
Non-Current Assets	'	'
Assets under capital lease, net	'	39,064
Current Liabilities	'	'
Related party payables	23,622	'
Capital lease obligations, current portion	10,286	50,574
Long-Term Liabilities	'	'
Capital lease obligations, net of current portion	$43,630	$120,960

ORGANIZATION_AND_NATURE_OF_OPE3

ORGANIZATION AND NATURE OF OPERATIONS (Detail Textuals) (USD $)	1 Months Ended	12 Months Ended
	Feb. 29, 2012	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2012	Dec. 31, 2011	Feb. 28, 2011
		Entity
Organization, Consolidation and Presentation Of Financial Statements [Abstract]	'	'	'	'	'	'
Increased number of authorized share capital	'	'	'	'	'	28,571,429
Increase in number of common stock	'	75,000,000	75,000,000	75,000,000	'	25,714,286
Common stock, par value (in dollars per share)	'	$0.00	$0.00	'	'	$0.00
Increase in number of preferred stock	'	2,857,143	2,857,143	'	'	2,857,143
Reverse stock split ratio	'7-for-1	'	'	'	'	'
Accumulated losses	'	($11,707,900)	($7,407,357)	'	'	'
Working capital surplus (deficit)	'	-5,435,000	'	'	'	'
Shareholders' deficit	'	($4,012,991)	($806,078)	'	($100,781)	'
Number of reporting entities	'	2	'	'	'	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of computation of basic and diluted earnings per share (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]	'	'
Net loss available to common stockholders (numerator)	($4,300,543)	($2,839,796)
Weighted average shares outstanding (denominator) (in shares)	18,743,738	15,983,905
Basic and diluted EPS (in dollars per share)	($0.23)	($0.18)

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of dilutive securities which were not included in computation of diluted EPS (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities excluded from computation of diluted EPS	10,436,327	5,186,285
Warrants	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities excluded from computation of diluted EPS	6,508,415	3,150,434
Common stock options	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities excluded from computation of diluted EPS	1,540,402	1,048,351
Convertible promissory notes	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Potentially dilutive securities excluded from computation of diluted EPS	2,387,510	987,500

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'
Depreciation methods of property and equipment	'straight-line method
Furniture and fixtures	'
Property, Plant and Equipment [Line Items]	'
Estimated useful lives for computing depreciation expense	'7 years
Medical equipment	'
Property, Plant and Equipment [Line Items]	'
Estimated useful lives for computing depreciation expense	'7 years
Other equipment	'
Property, Plant and Equipment [Line Items]	'
Estimated useful lives for computing depreciation expense	'3 to 5 years
Leasehold improvements	'
Property, Plant and Equipment [Line Items]	'
Estimated useful lives for computing depreciation expense	'five years or less

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]	'	'
Deferred revenue	$1,113,883	$502,795
Accrued expense	77,000	37,000
Advertising expense	570,000	359,000
Percentage of valuation allowance on deferred tax asset	100.00%	100.00%
Deferred rent	$251,597	$104,740

PROPERTY_AND_EQUIPMENT_Summary

PROPERTY AND EQUIPMENT - Summary of components of property and equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$3,178,520	$2,278,469
Less accumulated depreciation and amortization	-1,128,233	-967,160
Property and equipment, net	2,050,287	1,311,309
Equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	1,824,871	1,382,005
Furniture and fixtures	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	136,426	93,129
Leasehold improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$1,217,223	$803,335

PROPERTY_AND_EQUIPMENT_Detail_

PROPERTY AND EQUIPMENT (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Depreciation and amortization expense	$397,413	$282,068

PROPERTY_AND_EQUIPMENT_Detail_1

PROPERTY AND EQUIPMENT (Detail Textuals 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Accumulated amortization	$1,128,233	$967,160
Assets under capital leases	'	'
Property, Plant and Equipment [Line Items]	'	'
Assets under capital leases (gross)	159,000	511,000
Amortization expense	12,000	35,000
Accumulated amortization	$159,000	$471,000

PROPERTY_AND_EQUIPMENT_Detail_2

PROPERTY AND EQUIPMENT (Detail Textuals 2) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2013	Dec. 31, 2013
			Laser	Laser
			William Kirby, D.O., Inc	Unrelated Party
Property, Plant and Equipment [Line Items]	'	'	'	'
Number of asset purchased	'	'	3	3
Number of asset sold	'	'	'	3
Purchases of property and equipment	$593,059	$490,842	$75,000	'
Property and equipment, gross	3,178,520	2,278,469	'	228,000
Gain on sale of property and equipment	$62,366	'	'	$62,000

REVOLVING_LINE_OF_CREDIT_Detai

REVOLVING LINE OF CREDIT (Detail Textuals) (Revolving Credit Facility, USD $)	1 Months Ended
	Dec. 31, 2013
Revolving Credit Facility	'
Line of Credit Facility [Line Items]	'
Initial commitment for revolving line of credit	$1,300,000
Maximum revolving commitment	7,000,000
Increase in initial commitments at discretion of lender	1,300,000
Term of revolving loan	'6 months
Line of credit facility, description	'The term of the revolving loan is for six months subject to two automatic six month extensions as long as the Company is not in default on the credit agreement.
Amount of mandatory principal payment deposited in lockbox account	130,000
Amount of reduction in loan balance	130,000
Funds deposited in lockbox	$65,000
Percentage of funds deposited in lockbox for repayment of mandatory principal	2.00%

REVOLVING_LINE_OF_CREDIT_Detai1

REVOLVING LINE OF CREDIT (Detail Textuals 1) (Revolving Credit Facility, USD $)	1 Months Ended
	Dec. 31, 2013
	Organization
Line of Credit Facility [Line Items]	'
Interest rate for outstanding principal balance of the loan	10.00%
Line of credit facility, interest rate description	'The outstanding principal balance of the loan which is reduced by funds in the lockbox account bears interest at 10% per annum and requires a surcharge in the form of a receipts collection fee such that the aggregate interest and receipts collection fee do not exceed 1.5% of the outstanding principal per month.
Maximum percentage of outstanding Principal	1.50%
Asset monitoring fee per quarter	$1,500
Lender fees and related expenses	136,850
Cash paid for services in connection with loan	26,000
Description of common stock issued to lender	'Value of the common stock issued to the lender is not less than nor can ever be more than $125,000.
Vesting period specified for callable warrants	'3 years
Number of organizations affiliated to financial advisory firm	3
Sales	'
Line of Credit Facility [Line Items]	'
Minimum percentage of sales revenue	75.00%
Common Stock	'
Line of Credit Facility [Line Items]	'
Number of shares issued to lender	125,000
Threshold limit specified for value of common stock issued to lender	$125,000
Number of callable warrants to purchase common stock	39,000
Exercise price of warrants	0.78

NOTES_PAYABLE_Summary_of_compo

NOTES PAYABLE - Summary of components of notes payable (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'
Less current portion (net of unamortized discounts)	$716,531	$195,819
Notes payable, net	255,456	121,959
Notes payable	'	'
Debt Instrument [Line Items]	'	'
Total, notes payable	1,074,474	317,778
Less unamortized discount	-102,487	'
Less current portion (net of unamortized discounts)	-716,531	-195,819
Notes payable, net	255,456	121,959
Notes payable | Financed insurance premiums	'	'
Debt Instrument [Line Items]	'	'
Total, notes payable	'	4,510
Notes payable | Equipment promissory notes	'	'
Debt Instrument [Line Items]	'	'
Total, notes payable	674,474	313,268
Notes payable | Tenant improvement secured loans	'	'
Debt Instrument [Line Items]	'	'
Total, notes payable	100,000	'
Notes payable | Unsecured promissory notes	'	'
Debt Instrument [Line Items]	'	'
Total, notes payable	$300,000	'

NOTES_PAYABLE_Summary_of_futur

NOTES PAYABLE - Summary of future maturities of outstanding notes payable (Details 1) (Notes payable, USD $)	Dec. 31, 2013
Notes payable	'
Debt Instrument [Line Items]	'
2014	$716,531
2015	250,016
2016	5,440
Total	$971,987

NOTES_PAYABLE_Details_Textuals

NOTES PAYABLE (Details Textuals) (Notes payable, USD $)	1 Months Ended
	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
	Installment
Debt Instrument [Line Items]	'	'	'
Balance outstanding	'	$1,074,474	$317,778
Directors and Officer Liability Insurance Financing Agreement | Financed Insurance Premiums at 4.87 % Matures In January 2013	'	'	'
Debt Instrument [Line Items]	'	'	'
Term of agreement	'12 months	'	'
Debt instrument, principal amount	44,200	'	'
Debt instrument, interest rate	4.87%	'	'
Number of monthly installments for repayment of debt	10	'	'
Debt instrument, monthly installment	4,519	'	'
Balance outstanding	'	$0	$4,510

NOTES_PAYABLE_Detail_Textuals_

NOTES PAYABLE (Detail Textuals 1) (Notes payable, USD $)

Dec. 31, 2013

Dec. 31, 2012

Nov. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Feb. 28, 2011

Dec. 31, 2013

Dec. 31, 2012

31-May-11

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Nov. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Oct. 31, 2013

Dec. 31, 2013

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Non convertible promissory notes at 6% matures in October 2015

Non convertible promissory notes at 6% matures in October 2015

Non convertible promissory notes at 6% matures in October 2015

Non convertible promissory notes at 7% matures in January 2014

Non convertible promissory notes at 7% matures in January 2014

Non convertible promissory notes at 7% matures in January 2014

Non convertible promissory notes at 7% matures in June 2014

Non convertible promissory notes at 7% matures in June 2014

Non convertible promissory notes at 7% matures in June 2014

Non convertible promissory notes at 7% matures in June 2014

Non convertible promissory notes at 7% matures in June 2014

Non convertible promissory notes at 7% matures in June 2014

Non convertible promissory notes at 7% matures in June 2014

Non convertible promissory notes at 7% matures in June 2014

Non convertible promissory notes at 7% matures in June 2014

Non convertible promissory notes at 6% matures in May 2015

Non convertible promissory notes at 6% matures in May 2015

Non convertible promissory notes at 6% matures in May 2015

Non convertible promissory notes at 7% matures in November 2014

Non convertible promissory notes at 7% matures in November 2014

Non convertible promissory notes at 7% matures in November 2014

Non convertible promissory notes at 9% matures in February 2016

Non convertible promissory notes at 9% matures in February 2016

Non convertible promissory notes at 9% matures in February 2016

Non convertible promissory notes at 11% matures in February 2016

Non convertible promissory notes at 11% matures in February 2016

Non convertible promissory notes at 11% matures in February 2016

Non convertible promissory notes at 7% matures in March 2015

Non convertible promissory notes at 7% matures in March 2015

Non convertible promissory notes at 7% matures in March 2015

Non convertible promissory notes at 7% matures in November 2015

Non convertible promissory notes at 7% matures in November 2015

Non convertible promissory notes at 7% matures in November 2015

Non convertible promissory notes at 7% matures in November 2015

Non convertible promissory notes at 7% matures in November 2015

Non convertible promissory notes at 7% matures in November 2015

Non convertible promissory notes at 7% matures in December 2015

Non convertible promissory notes at 7% matures in December 2015

Computer and Telephone Equipment Financing Agreement

Computer and Telephone Equipment Financing Agreement

Computer and Telephone Equipment Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Computer and Telephone Equipment Financing Agreement

Computer and Telephone Equipment Financing Agreement

Computer and Telephone Equipment Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Computer and Telephone Equipment Financing Agreement

Computer and Telephone Equipment Financing Agreement

Computer and Telephone Equipment Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Computer and Telephone Equipment Financing Agreement

Computer and Telephone Equipment Financing Agreement

Computer and Telephone Equipment Financing Agreement

Computer and Telephone Equipment Financing Agreement

Computer and Telephone Equipment Financing Agreement

Computer and Telephone Equipment Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Hair Removal Device Financing Agreement

Purchase of Hair Removal Device Financing Agreement

Purchase of Hair Removal Device Financing Agreement

Purchase of Laser Financing Agreement

Purchase of Laser Financing Agreement

Installment

Installment

Installment

Installment

DRTHC I, LLC

DRTHC I, LLC

DRTHC I, LLC

Installment

DRTHC I, LLC

DRTHC I, LLC

DRTHC I, LLC

Installment

Installment

DRTHC I, LLC

DRTHC I, LLC

DRTHC I, LLC

DRTHC I, LLC

DRTHC II, LLC

DRTHC II, LLC

DRTHC I, LLC

DRTHC I, LLC

DRTHC II, LLC

Installment

Installment

Installment

Installment

Installment

Installment

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, principal amount

'

'

$64,157

'

'

$118,495

'

'

$17,515

'

'

$118,495

'

'

$59,920

'

'

$37,870

'

'

$67,996

'

'

$29,347

'

'

$37,524

'

'

$75,920

'

'

'

$114,000

'

$28,000

'

'

$248,000

'

Debt instrument, interest rate

'

'

6.00%

'

'

7.00%

'

'

7.00%

'

'

7.00%

'

'

7.00%

'

'

6.00%

'

'

7.00%

'

'

9.00%

'

'

11.00%

'

'

7.00%

'

'

'

7.00%

'

7.00%

'

'

7.00%

'

Number of monthly installments for repayment of debt

'

'

60

'

'

36

'

'

36

'

'

36

'

'

24

'

'

36

'

'

24

'

'

36

'

'

36

'

'

24

'

'

'

24

'

24

'

'

24

'

Debt instrument, monthly installment

'

'

1,241

'

'

3,700

'

'

539

'

'

3,700

'

'

2,683

'

'

1,148

'

'

3,044

'

'

1,037

'

'

1,199

'

'

3,399

'

'

'

5,104

'

1,254

'

'

11,104

'

Balance outstanding

$1,074,474

$317,778

'

$27,994

$40,779

'

$43,020

$54,030

'

$3,171

$9,201

'

$49,390

$67,186

'

$15,773

$45,715

'

$18,697

$31,008

'

$32,345

$65,349

'

$22,538

$0

'

$28,590

$0

'

$48,485

$0

$0

'

$109,561

'

$26,910

$0

$248,000

$0

NOTES_PAYABLE_Detail_Textuals_1

NOTES PAYABLE (Detail Textuals 2) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Nov. 30, 2012

Dec. 31, 2011

Dec. 31, 2013

Feb. 28, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Feb. 28, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jul. 31, 2013

Feb. 28, 2013

Aug. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Aug. 31, 2013

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Warrants

Warrants

Warrants

Tenant improvement secured loans

Tenant improvement secured loans

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Warrants

Warrants

Tenant improvement secured loans

Tenant improvement secured loans

Tenant improvement secured loans

Tenant improvement secured loans

Tenant improvement secured loans

Tenant improvement secured loans

Tenant improvement secured loans

Unsecured promissory notes of $120,000

Unsecured promissory notes of $120,000

Unsecured promissory notes of $120,000

Unsecured promissory notes of $120,000

Unsecured promissory notes of $200,000

Unsecured promissory notes of $200,000

Unsecured promissory notes of $200,000

Unsecured promissory notes of $200,000

Unsecured promissory notes of $20,000

Unsecured promissory notes of $20,000

Unsecured promissory notes of $20,000

Member

Note_Holder

Warrants

Warrants

Warrants

Member

Warrants

Warrants

Note_Holder

Warrants

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Secured senior convertible promissory note issued

'

'

'

'

'

'

'

'

'

'

'

$200,000

'

'

'

'

'

$120,000

'

'

'

$200,000

'

'

'

'

'

'

Percentage of shareholder

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

Debt instrument, interest rate

'

'

'

'

'

'

'

'

'

'

'

15.00%

'

'

'

'

'

15.00%

'

'

'

15.00%

'

'

'

'

'

'

Principal amount paid

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000

'

'

Interest paid

'

135,972

64,095

'

'

'

'

'

'

'

15,238

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,159

'

'

Number of note holders

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

Number of members

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

Balance outstanding

'

'

'

'

'

'

'

'

1,074,474

317,778

100,000

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

300,000

300,000

'

Number of shares called for warrants

'

'

'

'

'

'

115,240

218,750

'

'

'

'

'

'

115,240

220,000

218,750

'

'

'

120,000

'

'

'

200,000

'

'

310,893

Exercise price of warrants

'

'

'

0.64

'

1.28

0.6

0.6

'

'

'

'

'

'

0.6

0.6

0.6

'

'

'

0.6

'

'

'

0.6

'

'

0.6

Fair values of warrants

'

'

'

'

'

'

27,700

65,700

'

'

'

'

'

'

27,700

52,500

49,454

'

'

'

22,800

'

'

'

38,000

'

'

74,771

Fair value assumptions method used

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'

'

'

'Black-Scholes option pricing model

'

'

'

'Black-Scholes option pricing model

'

'

'Black-Scholes option pricing model

Value of common share (in dollars per share)

'

'

'

'

$0.49

'

$0.49

$0.49

'

'

'

'

'

'

$0.49

$0.49

$0.49

'

'

'

$0.49

'

'

'

$0.49

'

'

$0.49

Strike price

'

'

'

'

'

'

'

$0.75

'

'

'

'

'

'

$0.60

$0.60

$0.60

'

'

'

$0.60

'

'

'

$0.60

'

'

$0.60

Expected life

'

'

'

'

'

'

'5 years

'5 years

'

'

'

'

'

'

'5 years

'5 years

'5 years

'

'

'

'5 years

'

'

'

'5 years

'

'

'5 years

Risk free interest rate

'

'

'

'

'

'

1.73%

0.88%

'

'

'

'

'

'

1.73%

1.42%

0.08%

'

'

'

1.48%

'

'

'

1.48%

'

'

1.73%

Volatility rate

'

'

'

'

'

'

63.00%

72.00%

'

'

'

'

'

'

63.00%

63.00%

72.00%

'

'

'

63.00%

'

'

'

63.00%

'

'

63.00%

Expected dividend yield

'

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

0.00%

0.00%

0.00%

'

'

'

0.00%

'

'

'

0.00%

'

'

0.00%

Amortization of the debt discount

$0

$308,633

$39,570

'

'

'

'

'

'

'

'

'

$101,954

$0

'

'

'

'

$22,800

$0

'

'

$38,000

$0

'

'

$0

'

CONVERTIBLE_PROMISSORY_NOTES_S

CONVERTIBLE PROMISSORY NOTES - Summary of convertible promissory notes (Details) (Convertible promissory notes, USD $)	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'
Total, notes payable	$1,477,500	$592,500
Less unamortized discount	-201,125	-139,721
Less current portion (net of unamortized discounts)	-947,987	'
Convertible promissory notes, net	328,388	452,779
Secured senior subordinated convertible promissory notes	'	'
Debt Instrument [Line Items]	'	'
Total, notes payable	892,500	592,500
Senior subordinated convertible promissory notes	'	'
Debt Instrument [Line Items]	'	'
Total, notes payable	$585,000	'

CONVERTIBLE_PROMISSORY_NOTES_S1

CONVERTIBLE PROMISSORY NOTES - Summary of future maturities of outstanding convertible promissory notes (Details 1) (Convertible promissory notes, USD $)	Dec. 31, 2013
Convertible promissory notes	'
Debt Instrument [Line Items]	'
2014	$947,987
2015	328,388
Total	$1,276,375

CONVERTIBLE_PROMISSORY_NOTES_D

CONVERTIBLE PROMISSORY NOTES (Detail Textuals) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Nov. 30, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2013

Oct. 31, 2012

Sep. 30, 2012

Aug. 31, 2012

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Warrants

Warrants

Warrants

Warrants

Warrants

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Minimum

Maximum

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Minimum

Maximum

Warrants

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Secured senior convertible promissory note issued

'

'

'

'

'

'

'

'

'

'

$300,000

$87,500

$50,000

$255,000

$200,000

'

'

'

'

'

Conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.60

'

'

'

'

Debt instrument, interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

Balance outstanding

'

'

'

'

'

'

'

'

1,074,474

317,778

'

'

'

'

'

892,500

592,500

'

'

'

Number of shares called for warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,115,625

Exercise price of warrants

'

'

'

0.64

'

1.28

0.37

1

'

'

'

'

'

'

'

'

'

'

'

0.75

Fair values of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

217,225

Fair value assumptions method used

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Black-Scholes option pricing model

Value of common share (in dollars per share)

'

'

'

'

$0.49

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.49

Strike price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.75

Expected life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

Risk free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.52%

0.72%

'

Volatility rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

72.00%

Expected dividend yield

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

Beneficial conversion feature

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,066

'

'

'

'

Amortization of the debt discount

$0

$308,633

$39,570

'

'

'

'

'

'

'

'

'

'

'

'

$129,282

$39,570

'

'

'

CONVERTIBLE_PROMISSORY_NOTES_D1

CONVERTIBLE PROMISSORY NOTES (Detail Textuals 1) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Nov. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Sep. 30, 2013

Jul. 31, 2013

Jun. 30, 2013

31-May-13

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Warrants

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Notes payable

Senior subordinated convertible promissory notes

Senior subordinated convertible promissory notes

Senior subordinated convertible promissory notes

Senior subordinated convertible promissory notes

Senior subordinated convertible promissory notes

Aggregate senior subordinated convertible promissory note

Aggregate senior subordinated convertible promissory note

Aggregate senior subordinated convertible promissory note

Convertible promissory notes payable issued in September

Convertible promissory notes payable issued in September

Convertible promissory notes payable issued in September

Convertible promissory notes payable issued in December

Convertible promissory notes payable issued in December

Convertible promissory notes payable issued in December

Warrants

Warrants

Warrants

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Secured senior convertible promissory note issued

'

'

'

'

'

'

$50,000

$50,000

$35,000

$200,000

$250,000

'

'

'

'

'

'

'

'

'

Debt instrument, interest rate

'

'

'

'

'

'

7.00%

7.00%

7.00%

7.00%

7.00%

'

'

'

'

'

'

'

'

'

Fair values of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

92,283

'

'

9,000

'

'

9,000

Fair value assumptions method used

'

'

'

'

'

'

'

'

'

'

'

'

'

'Black-Scholes option pricing model

'

'

'Black-Scholes option pricing model

'

'

'Black - Scholes option pricing model

Value of common share (in dollars per share)

'

'

'

$0.49

'

'

'

'

'

'

'

'

'

$0.49

'

'

$0.49

'

'

$0.49

Strike price

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.78

'

'

$0.78

'

'

$0.78

Expected life

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'5 years

'

'

'5 years

Risk free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

0.58%

'

'

0.63%

'

'

0.63%

Volatility rate

'

'

'

'

'

'

'

'

'

'

'

'

'

63.00%

'

'

63.00%

'

'

63.00%

Expected dividend yield

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

0.00%

'

'

0.00%

Amortization of the debt discount

0

308,633

39,570

'

'

'

'

'

'

'

'

875

0

'

1,566

0

'

155

0

'

Conversion price lesser of:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Specified percentage qualified transaction price

'

'

'

'

'

'

75.00%

75.00%

75.00%

75.00%

75.00%

'

'

'

'

'

'

'

'

'

Conversion price

'

'

'

'

'

'

$0.65

$0.65

$0.65

$0.65

$0.65

'

'

'

'

'

'

'

'

'

Number of warrant issued to purchase shares

'

'

'

'

'

'

76,923

76,923

746,157

746,157

746,157

'

'

'

'

'

'

'

'

'

Percentage of conversion price

'

'

'

'

'

'

120.00%

120.00%

120.00%

120.00%

120.00%

'

'

'

'

'

'

'

'

'

Term of warrant

'

'

'

'

'

'

'3 years

'3 years

'3 years

'3 years

'3 years

'

'

'

'

'

'

'

'

'

Balance outstanding

'

'

'

'

$1,074,474

$317,778

'

'

'

'

'

$485,000

'

'

$50,000

'

'

$50,000

'

'

Conversion price

'

'

'

'

'

'

$0.78

$0.78

$0.78

$0.78

$0.78

'

'

'

'

'

'

'

'

'

CAPITAL_LEASE_OBLIGATIONS_RELA2

CAPITAL LEASE OBLIGATIONS (RELATED PARTY) - Summary of components of capital lease obligations (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Capital Leased Assets [Line Items]	'	'
Total capital lease obligations	$53,916	$171,534
Less current maturities	10,286	50,574
Long-term portion	43,630	120,960
Equipment | $199,610 capital lease obligation on equipment, bears interest at 9.65% per annum, monthly in principal and interest installments of $2,704 and matures in May 2018	'	'
Capital Leased Assets [Line Items]	'	'
Total capital lease obligations	53,916	134,827
Equipment | $69,200 capital lease obligation on equipment, bears interest at 14.95% per annum, monthly in principal and interest installments of $1,644 and matures in May 2013	'	'
Capital Leased Assets [Line Items]	'	'
Total capital lease obligations	'	7,920
Equipment | $57,750 capital lease obligation on equipment, bears interest at 9.15% per annum, monthly in principal and interest installments of $1,203 and matures in May 2013	'	'
Capital Leased Assets [Line Items]	'	'
Total capital lease obligations	'	7,029
Equipment | $72,375 capital lease obligation on equipment, bears interest at 9.11% per annum, monthly in principal and interest installments of $2,123 and matures in April 2014	'	'
Capital Leased Assets [Line Items]	'	'
Total capital lease obligations	'	$21,758

CAPITAL_LEASE_OBLIGATIONS_RELA3

CAPITAL LEASE OBLIGATIONS (RELATED PARTY) - Summary of components of capital lease obligations (Parentheticals) (Details) (USD $)	Dec. 31, 2013
Capital Leased Assets [Line Items]	'
Principal and interest installments monthly payments	$12,515
Equipment | $199,610 capital lease obligation on equipment, bears interest at 9.65% per annum, monthly in principal and interest installments of $2,704 and matures in May 2018	'
Capital Leased Assets [Line Items]	'
Capital lease obligation on equipment	199,610
Lease bears interest per annum	9.65%
Principal and interest installments monthly payments	2,704
Equipment | $69,200 capital lease obligation on equipment, bears interest at 14.95% per annum, monthly in principal and interest installments of $1,644 and matures in May 2013	'
Capital Leased Assets [Line Items]	'
Capital lease obligation on equipment	69,200
Lease bears interest per annum	14.95%
Principal and interest installments monthly payments	1,644
Equipment | $57,750 capital lease obligation on equipment, bears interest at 9.15% per annum, monthly in principal and interest installments of $1,203 and matures in May 2013	'
Capital Leased Assets [Line Items]	'
Capital lease obligation on equipment	57,750
Lease bears interest per annum	9.15%
Principal and interest installments monthly payments	1,203
Equipment | $72,375 capital lease obligation on equipment, bears interest at 9.11% per annum, monthly in principal and interest installments of $2,123 and matures in April 2014	'
Capital Leased Assets [Line Items]	'
Capital lease obligation on equipment	72,375
Lease bears interest per annum	9.11%
Principal and interest installments monthly payments	$2,123

CAPITAL_LEASE_OBLIGATIONS_RELA4

CAPITAL LEASE OBLIGATIONS (RELATED PARTY) - Summary of future minimum capital lease payments (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Leases [Abstract]	'	'
2014	$15,041	'
2015	15,041	'
2016	15,041	'
2017	15,041	'
2018	6,267	'
Total minimum lease payments	66,431	'
Less amount representing interest	-12,515	'
Present value of minimum lease payments	53,916	'
Less current portion	-10,286	-50,574
Long-term portion	$43,630	$120,960

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Detail Textuals) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2010	Dec. 31, 2013	Dec. 31, 2012
			William Kirby, D.O., Inc	William Kirby, D.O., Inc	William Kirby, D.O., Inc	William Kirby, D.O., Inc	William Kirby, D.O., Inc	William Kirby, D.O., Inc	William Kirby, D.O., Inc
			Clinic		Management Services Agreement	Management Services Agreement	Medical Director Agreement	Medical Director Agreement	Medical Director Agreement
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'
Number of clinics in southern California	'	'	4	'	'	'	'	'	'
Due from related party	'	$189,484	'	$189,484	$0	$189,484	'	'	'
Initial term of agreement	'	'	'	'	'	'	'5 years	'	'
Automatic renewal term of agreement	'	'	'	'	'	'	'5 years	'	'
Annual payment for services	'	'	'	'	'	'	250,000	'	'
Related party payables	$23,622	'	$23,622	'	'	'	'	$20,833	$0
Number of clinics	'	'	3	'	'	'	'	'	'

EQUITY_Summary_of_stock_option

EQUITY - Summary of stock option activity (Details) (Stock options, USD $)	12 Months Ended
	Dec. 31, 2013
Stock options	'
Number of Options	'
Outstanding at December 31, 2012	1,048,351
Granted	750,845
Exercised	-35,700
Forfeited or Expired	-223,094
Outstanding at December 31, 2013	1,540,402
Exercisable at December 31, 2013	753,609
Vested and expected to vest at December 31, 2013	1,540,402
Weighted Average Exercise Price per Share	'
Outstanding at December 31, 2012	$0.39
Granted	$0.52
Exercised	$0.49
Forfeited or Expired	$0.38
Outstanding at December 31, 2013	$0.45
Exercisable at December 31, 2013	$0.44
Vested and expected to vest at December 31, 2013	$0.45
Weighted Average Grant-Date Fair Value per Share	'
Outstanding at December 31, 2012	$0.39
Granted	$0.44
Exercised	$0.49
Forfeited or Expired	$0.38
Outstanding at December 31, 2013	$0.44
Exercisable at December 31, 2013	$0.43
Vested and expected to vest at December 31, 2013	$0.44

EQUITY_Summary_of_warrant_acti

EQUITY - Summary of warrant activity (Details 1) (Warrants)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrants	'	'
Shares	'	'
Outstanding	3,150,434	269,558
Granted	3,562,914	2,949,633
Exercised	'	'
Expired or cancelled	-204,933	-68,757
Exercisable at December 31, 2012	6,508,415	3,150,434
Weighted average exercise price	'	'
Outstanding	0.64	1.28
Granted	0.73	0.62
Exercised	'	'
Expired or cancelled	0.93	2.13
Exercisable	'	0.64
Weighted average remaining contractual life (in years), Outstanding	'4 years 6 months	'2 years 10 months 24 days
Weighted average remaining contractual life (in years), Granted	'4 years	'4 years 7 months 6 days
Weighted average remaining contractual life (in years), Exercisable	'3 years 9 months 18 days	'4 years 6 months

EQUITY_Summary_of_warrants_out

EQUITY - Summary of warrants outstanding and exercisable (Details 2) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Warrants Execise price $.37-1.00

Warrants Execise price $.37-1.00

Warrants Execise price $.37-1.00

Warrants Execise price $.37-1.00

Warrants Execise price $.37-1.00

Warrants Execise price $.37-1.00

Warrant Exercise price $.37

Warrant Exercise price $.37

Warrant Exercise price $.59-.78

Warrant Exercise price $.59-.78

Warrant Exercise price $.59-.78

Warrant Exercise price $.59-.78

Warrant Exercise price $.49-.75

Warrant Exercise price $.49-.75

Warrant Exercise price $.49-.75

Warrant Exercise price $.49-.75

Warrant Exercise price $.59-1.00

Warrant Exercise price $.59-1.00

Warrant Exercise price $.59-1.00

Warrant Exercise price $.59-1.00

Minimum

Maximum

Weighted Average

Weighted Average

Minimum

Maximum

Weighted Average

Minimum

Maximum

Weighted Average

Minimum

Maximum

Weighted Average

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares under warrants

6,508,415

3,150,434

269,558

'

'

'

128,840

'

915,651

'

'

'

2,949,633

'

'

'

2,514,291

'

'

'

Range of exercise prices

'

0.64

1.28

0.37

1

'

0.37

'

'

0.59

0.78

'

'

0.49

0.75

'

'

0.59

1

'

Expiration date

'

'

'

'

'

'

'2015

'

'2016

'

'

'

'2017

'

'

'

'2018

'

'

'

Weighted average exercise price

'

'

'

'

'

$0.62

'

$0.37

'

'

'

$0.77

'

'

'

$0.62

'

'

'

$0.71

EQUITY_Detail_Textuals

EQUITY (Detail Textuals) (USD $)

12 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

31-May-13

Mar. 31, 2013

Apr. 30, 2013

Mar. 31, 2013

Oct. 31, 2012

Sep. 30, 2012

Aug. 31, 2012

Jul. 31, 2012

Mar. 31, 2012

Mar. 31, 2012

Mar. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Jan. 31, 2013

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Stock options

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Management and Other Affiliates

Independent Director

Consultants

Non Executive Employee

Director

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of common stock in private placement

'

'

'

'

'

90,910

136,365

597,960

266,225

444,693

1,580,613

606,610

337,428

'

'

'

'

Proceeds from sale of common stock through private placement

'

'

'

'

'

$50,000

$75,000

$293,001

$130,450

$217,899

$774,500

$297,240

$165,340

'

'

'

'

Number of shares issued pursuant to stock option exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

35,700

Proceeds from exercise of stock options

$17,493

$7,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$17,500

Number of shares issued for services

'

'

13,636

145,455

423,061

'

'

87,930

'

'

'

'

'

270,000

153,061

'

'

Number of independent director

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

Issue price of shares issued for services

'

'

$0.49

$0.49

$0.49

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued to lender

'

'

125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued as additional compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,300

'

EQUITY_Detail_Textuals_1

EQUITY (Detail Textuals 1) (USD $)

12 Months Ended

1 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

31-May-12

Mar. 31, 2013

Nov. 30, 2012

Jul. 31, 2012

Oct. 31, 2013

Mar. 31, 2013

Nov. 30, 2012

Mar. 31, 2012

Mar. 31, 2013

Mar. 31, 2013

Jun. 30, 2013

Oct. 31, 2013

Jul. 31, 2013

Jun. 30, 2013

Mar. 31, 2013

Jan. 31, 2013

Nov. 30, 2012

Sep. 30, 2012

Oct. 31, 2013

Mar. 31, 2013

Oct. 31, 2013

Mar. 31, 2013

Nov. 30, 2012

Stock options

Stock options

Stock options

Stock options

Non-qualified stock options

Non-qualified stock options

Non-qualified stock options

Non-qualified stock options

Non-qualified stock options

Non-qualified stock options

Non-qualified stock options

Non-qualified stock options

Non-qualified stock options

Non-qualified stock options

Incentive stock options

Incentive stock options

Incentive stock options

Incentive stock options

Incentive stock options

Incentive stock options

Incentive stock options

Incentive stock options

Incentive stock options

Incentive and non-qualified stock options to employees

Incentive and non-qualified stock options to employees

Incentive and non-qualified stock options to employees

General and administrative expense

General and administrative expense

Director

Director

Consultants

Consultants

Employee of William Kirby, D.O., Inc.

Employee of William Kirby, D.O., Inc.

Employee of William Kirby, D.O., Inc.

Employee of William Kirby, D.O., Inc.

Five members of medical advisory board

Five members of medical advisory board two

New members of medical advisory board

Employees

Employees

Employees

Employees

Employees

Employees

Employees

Executive officers

Executive officers

Common Stock

Member

Member

Employee

Member

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period shares purchase of common stock

'

'

750,845

'

'

10,714

20,000

5,000

35,700

6,088

6,517

10,337

62,500

10,000

10,000

10,000

2,513

112,727

212,413

13,264

61,225

21,824

25,000

7,327

24,041

'

'

'

Share based compensation vesting period

'

'

'

'

'

'

'

'5 years

'4 months

'

'

'

'4 years

'

'

'

'

'4 years

'4 years

'

'12 months

'

'5 years

'

'

'

'

'

Weighted average exercise price per share of the options granted

'

'

$0.52

'

'

'

$0.49

$0.49

$0.49

'

'

'

$0.49

$0.49

$0.55

$0.55

'

$0.55

$0.55

'

$0.49

'

$0.49

'

'

$0.55

$0.49

$0.49

Fair value assumptions, method used

'

'

'

'

'

'

'Black-Scholes option pricing method

'Black-Scholes option-pricing model

'Black-Scholes option-pricing model

'

'

'

'Black-Scholes option-pricing model

'Black-Scholes option-pricing model

'Black-Scholes option-pricing model

'Black-Scholes option pricing method

'

'Black-Scholes option-pricing model

'Black-Scholes option-pricing model

'

'Black-Scholes option-pricing model

'

'Black-Scholes option-pricing model

'

'

'Black-Scholes option-pricing model

'Black-Scholes option-pricing model

'Black-Scholes option-pricing model

Intrinsic value of options exercised

'

'

'

'

'

'

$52,000

$1,500

$12,200

'

'

'

$18,000

$13,400

$13,400

$2,503

'

$28,100

$53,200

'

$17,300

'

$7,300

'

'

$3,900

$14,000

$9,400

Value of common share (in dollars per share)

'

'

'

'

'

'

$0.49

$0.49

$0.49

'

'

'

$0.49

$0.49

$0.49

$0.49

'

$0.49

$0.49

'

$0.49

'

$0.49

'

'

$0.49

$0.49

$0.49

Strike price

'

'

'

'

'

'

$0.49

$0.49

$0.49

'

'

'

$0.49

$0.49

$0.49

$0.55

'

$0.55

$0.55

'

$0.49

'

$0.49

'

'

$0.55

$0.49

$0.49

Expected term

'

'

'

'

'

'

'5 years

'5 years

'5 years

'

'

'

'5 years

'5 years

'5 years

'5 years

'

'5 years

'5 years

'

'5 years

'

'5 years

'

'

'5 years

'5 years

'5 years

Risk free interest rate

'

'

'

'

'

'

0.63%

0.63%

0.60%

'

'

'

1.19%

0.63%

0.63%

1.07%

'

1.42%

1.07%

'

0.67%

'

0.67%

'

'

1.41%

0.63%

0.63%

Expected volatility rate

'

'

'

'

'

'

73.00%

73.00%

73.00%

'

'

'

72.00%

73.00%

73.00%

64.00%

'

63.00%

64.00%

'

73.00%

'

73.00%

'

'

63.00%

73.00%

73.00%

Expected dividend rate

'

'

'

'

'

'

0.00%

0.00%

0.00%

'

'

'

0.00%

0.00%

0.00%

0.00%

'

0.00%

0.00%

'

0.00%

'

0.00%

'

'

0.00%

0.00%

0.00%

Equity issuance, per share amount

'

'

'

'

'

$0.37

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation expense

'

'

'

136,000

71,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from exercise of stock options

$17,493

$7,900

'

'

'

$7,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of members

'

'

'

'

'

2

3

'

'

'

'

'

'

'

5

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares vesting 50% immediately

'

'

'

'

'

'

45,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of vesting

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

25.00%

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of shares vesting each anniversary

'

'

'

'

'

'

25.00%

'

'

'

'

'

'

25.00%

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

Number of employee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

EQUITY_Detail_Textuals_2

EQUITY (Detail Textuals 2) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Nov. 30, 2012

Dec. 31, 2011

Dec. 31, 2013

31-May-13

Mar. 31, 2013

Jan. 31, 2013

Jul. 31, 2013

Oct. 31, 2013

Aug. 31, 2012

Nov. 30, 2012

Dec. 31, 2013

Feb. 28, 2013

Dec. 31, 2013

Oct. 31, 2013

Aug. 31, 2013

Apr. 30, 2013

Mar. 31, 2013

Oct. 31, 2012

Sep. 30, 2012

Aug. 31, 2012

Jul. 31, 2012

Mar. 31, 2012

Dec. 31, 2013

Sep. 30, 2013

Jan. 31, 2013

Oct. 31, 2012

Sep. 30, 2012

Aug. 31, 2012

31-May-12

Jul. 31, 2013

Dec. 31, 2013

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Warrants

Service provider

Service provider

Service provider

Employees

Two employee

Consultants

Consultants

Third party

Tenant improvement secured loans

Tenant improvement secured loans

Unsecured promissory notes

Unsecured promissory notes

Unsecured promissory notes

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private Placement

Private placement in May, June And July 2013

Member

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Secured senior subordinated convertible promissory notes

Member

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares called for warrants

'

'

'

'

'

39,000

34,090

76,530

30,613

84,545

450,000

400,000

20,000

115,240

218,750

310,893

200,000

120,000

68,183

102,274

340,037

133,113

222,346

790,307

303,305

76,923

76,923

375,000

109,275

'

318,750

250,000

186,537

746,157

Number of common stock called for warrants issued to board of directors and their affiliates

'

'

'

'

'

'

'

'

'

'

'

'

'

'

62,500

'

'

'

'

'

'

'

'

'

168,714

'

'

250,000

'

62,500

'

250,000

'

'

Exercise price of warrants

'

'

0.64

'

1.28

0.62

0.65

0.595

0.595

0.65

1

0.49

0.49

0.6

0.6

0.6

0.6

0.6

0.65

0.65

0.595

0.595

0.595

0.595

0.595

0.78

0.78

0.75

0.75

0.75

0.75

0.75

0.78

'

Share price

'

'

'

$0.49

'

$0.78

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

$0.49

Strike price

'

'

'

'

'

$0.49

'

'

'

'

'

'

'

'

$0.75

'

$0.60

$0.60

'

'

'

'

'

'

'

$0.78

$0.78

$0.75

$0.75

$0.75

$0.75

$0.75

$0.78

$0.78

Fair value assumptions method used

'

'

'

'

'

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

'Black-Scholes option pricing model

Expected life

'

'

'

'

'

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'5 years

'2 years 6 months

Risk free interest rate

'

'

'

'

'

0.58%

0.79%

0.62%

0.62%

1.41%

1.41%

0.62%

0.63%

1.73%

0.88%

1.73%

1.30%

1.48%

0.74%

0.88%

0.59%

0.62%

0.59%

0.60%

1.03%

0.63%

0.63%

0.88%

0.72%

0.62%

0.51%

0.72%

1.07%

0.58%

Volatility rate

'

'

'

'

'

63.00%

64.00%

72.00%

72.00%

63.00%

63.00%

72.00%

73.00%

63.00%

72.00%

63.00%

63.00%

63.00%

64.00%

72.00%

73.00%

72.00%

72.00%

72.00%

70.00%

63.00%

63.00%

72.00%

72.00%

72.00%

72.00%

72.00%

64.00%

63.00%

Expected dividend yield

'

'

'

'

'

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

0.00%

Fair values of warrants

'

'

'

'

'

$4,300

$7,811

$20,500

$8,200

$19,400

$80,300

$114,800

$5,800

$27,700

$65,700

$74,800

$38,000

$28,700

$15,600

$26,000

$92,600

$35,500

$59,300

$210,800

$79,500

$10,900

$10,900

$89,500

$20,125

$9,350

$58,650

$60,100

$36,250

$91,400

Condition for number of shares issuable under warrant pursuant to conversion of debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 100% of the number of conversion shares and the strike price adjusted to 120% of the conversion price.

'In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 100% of the number of conversion shares and the strike price adjusted to 120% of the conversion price.

'

'

'

'

'

'In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 25% of the number of conversion shares and the strike price adjusted to 120% of the conversion price.

'In the event that the convertible note is converted, the number of shares issuable under the warrant will be adjusted to 25% of the number of conversion shares and the strike price adjusted to 120% of the conversion price.

Number of members

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

Warrant liabilities

$116,690

$1,600

'

'

'

$5,400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,200

'

'

'

'

'

'

'

$91,400

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES - Summary of aggregate minimum future payments required on operating leases (Details) (USD $)	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
2014	$635,811
2015	665,821
2016	678,707
2017	501,659
2018	213,531
Thereafter	148,873
Aggregate minimum future payments	$2,844,402

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Detail Textuals)	12 Months Ended
	Dec. 31, 2013
Minimum	'
Operating Leased Assets [Line Items]	'
Percentage of annual escalation provisions	3.00%
Period for options renewal	'3 years
Maximum	'
Operating Leased Assets [Line Items]	'
Percentage of annual escalation provisions	4.00%
Period for options renewal	'5 years

COMMITMENTS_AND_CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Detail Textuals 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
William Kirby, D.O., Inc	'	'
Operating Leased Assets [Line Items]	'	'
Rent expense relating to related party leases	$42,000	$198,000
Unrelated Third Party	'	'
Operating Leased Assets [Line Items]	'	'
Rent expense relating to related party leases	$586,000	$239,000

INCOME_TAXES_Summary_of_compon

INCOME TAXES - Summary of components of provision for income taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Current	'	'
Federal	'	'
State	800	800
Total current tax	800	800
Deferred	'	'
Federal	'	'
State	'	'
Total	$800	$800

INCOME_TAXES_Summary_of_differ

INCOME TAXES - Summary of difference between income taxes at statutory rates and amount presented in financial statements (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Computed expected income tax benefit at federal statutory rates	34.00%	34.00%
Addition to (reduction in) income taxes resulting from:	'	'
State income taxes, net of federal benefit	6.00%	6.00%
Other	'	'
Valuation allowance	-40.00%	-40.00%
Total	0.00%	0.00%

INCOME_TAXES_Summary_of_signif

INCOME TAXES - Summary of significant components of deferred taxes (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Net operating loss carryforwards	$4,286,000	$3,150,000
Other	708,000	209,000
Less valuation allowance	-4,994,000	-3,359,000
Net deferred tax assets	'	'

INCOME_TAXES_Detail_Textuals

INCOME TAXES (Detail Textuals) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Examination [Line Items]	'	'
Federal tax net operating loss carryforwards	$9,300,000	$6,200,000
State tax net operating loss carryforwards	8,000,000	5,500,000
Percentage of valuation allowance	100.00%	100.00%
Change in deferred tax assets valuation allowance	$1,635,000	$1,081,000
Domestic Tax Authority	'	'
Income Tax Examination [Line Items]	'	'
Year under examination	'3 years	'
State and Local Jurisdiction	'	'
Income Tax Examination [Line Items]	'	'
Year under examination	'4 years	'